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SUMMARY 
Drug resistance can be defined as the failure of a drug to exert its expected effect on 
pharmacological biomarkers. Resistance is an inherent challenge to pharmacotherapy with 
treatments that are generally considered as safe and effective. Limited effectiveness in 
specific patient subgroups can result from a broad spectrum of factors, which can be 
classified into pharmaco-genetic, cellular and clinical factors. However, drug response in 
daily life is the result of the interplay between numerous contributors. Thus, studying the 
impact of certain factors is of limited value if others are not controlled for. 
Non-adherence in outpatient treatment is common and constitutes a major challenge to 
translate drug efficacy known from controlled conditions in clinical trials into daily life 
effectiveness. Drug resistance and the lack of biomarker target achievement in chronic 
outpatient treatment is likely to be confounded by non-adherence rather than being a simple 
function of pharmaco-genetic factors. Drug drug interactions constitute another clinical factor 
that may add to the challenge of drug resistance. Both non-adherence and exposure to drug 
drug interactions can be controlled for by the application of a new technology for adherence 
monitoring that was developed in the framework of this thesis. 
Personalised medicine aims at tailoring drug treatments to specific patient subgroups. 
Additionally to biomarker characteristics of a patient, factors affecting the patient’s ability to 
adhere to a certain regimen should be considered when analysing inter-individual variability 
of drug response. Interventions to overcome drug resistance must incorporate any of the 
identified factors when effectiveness and toxicity of outpatient therapy should be optimized 
by a truly personalised approach. 
It was the aim of this thesis to apply this multifactorial model of drug resistance to 
cardiovascular medication in outpatients. A special focus was set on antiplatelet therapy with 
aspirin and clopidogrel, for which a prospective study with the application of multidrug 
adherence monitoring was designed and executed. In a second prospective study aimed at 
comparing effectiveness of oral vitamin B12 substitution in comparison to intramuscular 
injections, the adherence monitoring technique should be employed to track adherence to a 
single drug. 
In project A, we studied the prevalence of unreached biomarker targets in patients with 
lipid-lowering drugs (LLD) and antihypertensive drugs (AHT). For this investigation, a 
retrospective analysis of data that was collected in a population-based cross sectional study 
with 4380 patients was performed. Of 863 patients that were treated with lipid lowering 
SUMMARY 
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and/or antihypertensive drugs, 306 (35.5%) did not reach the respective therapeutic with at 
least one of the treatments. The rates of missed target attainment were 25.8% (LLD) and 
36.3% (AHT). These impressive rates may serve as estimates of the burden of drug 
resistance in an unselected outpatient population. According to the multifactorial model of 
drug resistance, disease factors, clinical and pharmaco-genetic factors are presumed 
contributors. Patients with concomitant prescription of LLD and AHT were significantly less 
likely to miss their biomarker targets in both treatments. This may be due to optimised 
adherence and disease awareness in patients that were prescribed both treatments and 
certainly underscores the need to involve clinical factors when investigating factors to 
resistance. 
Consequently, a prospective study on antiplatelet resistance involving multidrug adherence 
monitoring was designed in project B. Within this project, the polymedication adherence 
monitoring system (POEMS) was developed, which aimed at monitoring of the patient’s 
adherence to all his oral solid drugs. This study should be the first to allow evaluating the 
impact of drug drug interactions, pharmaco-genetic polymorphisms and disease factors 
under prospectively measured objective adherence in chronic antiplatelet therapy. The study 
was approved by the ethics committee of Aargau and Solothurn, Switzerland and was 
executed between June 2010 and July 2011 in Olten, Switzerland. 
The results of the study were analysed and worked up in the projects C and D. In project 
C1, the pattern of timing adherence of the patients that were included in the parent study on 
antiplatelet resistance was analysed. The polymedication electronic monitoring system 
proved to be a suitable tool to collect comprehensive data on multidrug adherence and 
allowed identifying 7:41 h, 12:09 h and 18:36 h as median intake times of the morning, 
midday and evening doses. Significant delays of the morning drug intake times were 
observed on Saturday and Sunday, and the time variability of drug intake was generally lower 
in the morning than in the evening. A tendency towards lower LDL-C values in patients with 
a lower time variability of the lipid lowering drug (LLD) containing dose was observed, 
suggesting that effectiveness of LLD may depend on the precision of timing adherence. 
Subjective adherence measures such as the scores calculated from the Believes about 
Medicines Questionnaire (BMQ) and the Morisky Medication Adherence Scale (MMAS-8) 
were neither associated with objective adherence parameters nor predictive of LDL-C levels 
in patients with lipid lowering therapy. In project C2, the use of POEMS was demonstrated 
in an exemplary case of a patient whose irrational timing adherence could be disclosed and 
partly corrected by the intervention of a pharmacist. 
SUMMARY 
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In project D, the results of the main study on antiplatelet resistance with aspirin and 
clopidogrel were evaluated. The evaluable patients (N=82) were analyzed separately in two 
overlapping samples of 69 aspirin users and 32 clopidogrel users. After adherence 
monitoring, resistance was found in 20% of the aspirin users and 25% of the clopidogrel 
users. Non-adherence was dismissed as a major contributor to drug resistance with aspirin 
and clopidogrel in chronic outpatient treatment due to the absence of significant differences 
of platelet aggregation before and after adherence monitoring. Multidrug adherence 
monitoring with POEMS allowed to precisely measuring the exposure to drug drug 
interactions (DDIs). Actual exposure to DDIs was lower than when referring to prescription 
data. The consideration of data from multidrug adherence when analyzing the impact of 
DDIs prevented from misleading results due to dilution effects by non-adherence to 
interfering drugs. The potential DDI of clopidogrel with high-dose lipophilic statins was found 
probable and may result in significant effects when analyzing a higher number of patients. 
Statistically significant effects on aspirin resistance were found for diabetes mellitus and 
systemic inflammation. These disease factors were also most probable to have an impact on 
antiplatelet resistance with clopidogrel, while the impact of CYP2C19 polymorphism on 
antiplatelet resistance seemed negligible. 
The consideration of adherence as an independent variable when studying resistance or 
response to oral drug therapy has further been implemented in project E, which aimed at 
demonstrating the non-inferiority of oral high-dose vitamin B12 substitution in comparison to 
intramuscular injections. Other than in the previous project with multidrug adherence 
monitoring, POEMS was planned to be employed for tracking adherence with oral vitamin 
B12 only. The study to compare oral and i.m. substitution of vitamin B12 has been approved 
by the ethics committee of Aargau and Solothurn, Switzerland and was successfully notified 
by Swissmedic, the Swiss agency for therapeutic products in March 2012. This study will be 
executed outside of this thesis. 
In conclusion this thesis showed that the investigation of antiplatelet resistance by the 
application of this unique approach with prospective adherence monitoring to all oral solid 
drugs is feasible. We were able to characterise the temporal pattern of drug intake and 
found associations between the timing variability of drug intake and attained LDL-C levels in 
patients with lipid lowering therapy. In antiplatelet therapy with aspirin and clopidogrel, 
resistance rates of 20% and 25% could be confirmed despite prospective adherence 
monitoring. POEMS allowed to assess the precise exposure to DDIs and to analyse the 
timing effect of the DDI between clopidogrel and lipophilic statins. The results that were 
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found with this methodology supported staggered versus concomitant intake of these 
potentially interfering drugs. 
The following conclusions could be drawn:  
x The POEMS technology allowed collecting data on multidrug timing adherence which 
has not been reported before. 
x The new technology and procedures were well accepted by the patients. 
x Objectively measured timing adherence parameters are suitable to describe intake 
characteristics of a patient. Significant deviations from prescribed drug intake can be 
observed, and intake characteristics vary in different patients’ groups. 
x The combination of the weekly multidrug blister together with the electronic 
adherence monitoring was effective to rule out non-adherence. 
x The association between the time variability of the LLD intake and LDL-C levels 
suggests an impact of timing adherence on statin effectiveness. 
x Antiplatelet resistance in outpatients with maintenance doses of aspirin and 
clopidogrel is common. Approximately 20% of patients with aspirin and 25% of the 
patients with clopidogrel are affected.  
x Aspirin resistance as measured with the MULTIPLATE® analyser is rather a 
dichotomous phenomenon, while platelet aggregation with clopidogrel is a 
continuous measure.  
Our recommendations for daily practice are: 
x If there is doubt about the effectiveness of the treatment with aspirin or clopidogrel, 
the investigation by specific in vitro platelet aggregation tests is recommended. If the 
test result does not comply with the expected inhibition of platelet aggregation, the 
further investigation should involve multidrug adherence monitoring to rule out non-
adherence and to measure the exposure to potentially interfering drugs. If the 
insufficient inhibition of platelets persists after one week of multidrug adherence 
monitoring, measures should be taken to optimize antiplatelet therapy. In the case of 
clopidogrel, CYP2C19 genotyping should be part of the workup. Comprehensive 
consideration of the test results, together with medication and clinical data should 
allow finding alternative treatments to prevent the patient from the potential clinical 
consequences of antiplatelet drug resistance. 
x Multidrug adherence measurement may serve as a useful diagnostic tool to disclose 
the timing adherence pattern of polymedicated patients. The adherence report is 
SUMMARY 
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useful to visualize the adherence pattern and may serve as a useful background to 
discuss timing adherence issues together with the patient. 
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1. GENERAL INTRODUCTION 
1.1. DRUG RESISTANCE 
The term “drug resistance” has been most commonly applied for antimicrobial drugs, where 
it is used to describe the ability of the pathogen to emerge from the antibiotic pressure due 
to the development of specific mechanisms of resistance. A broader definition involves the 
failure of any drug to exert its expected measurable effect on the treated subject, 
irrespective of the cause. Other than “treatment failure”, which is used to address clinical 
outcomes, drug resistance refers to an intermediate outcome which can notably be 
measured with a biomarker that is predictive of the drug’s effectiveness. 
This broader definition of drug resistance has been the background of its application in 
various fields of drug therapy. Drug resistance has become a key issue in cancer therapy, 
but has also found application in the pharmacologic treatment of epilepsy, hypertension or 
depression, just to name a few examples [1-4]. Incomparable attention has been attracted by 
the phenomenon of antiplatelet drug resistance, which has mainly been nourished by the 
scientific debate on clopidogrel response variability and the contribution of pharmaco-genetic 
factors [5]. 
The underlying causes for drug resistance are numerous and reach from clinical (e.g. patient 
non-adherence) to pharmaco-genetic (e.g. polymorphic expression of drug targets) 
contributors. Their impact on resistance varies widely and depends on the pharmacological 
properties of the drug. In many cases, resistance is rather a gradual phenomenon which is 
reflected by a continuous measure, for which the binary categorisation into “resistant” and 
“responder” is an unjustified oversimplification. In the area of personalised medicine, the 
factors associated with drug resistance should be identified and concepts to overcome the 
negative outcomes associated with drug resistance should be developed to guide patients 
and their caregivers to rational and evidence based optimization of the implemented drug 
therapies. 
1.1.1. ANTIPLATELET DRUG RESISTANCE 
Aspirin has been used for the prevention and treatment of thrombosis for many years and 
offers an approximately 25% reduction for stroke, myocardial infarction, and cardiovascular 
death [6]. The mechanism of its antiplatelet effects has first been described in 1971 [7]. 
Other antiplatelet agents such as cilostazol and later ticlopidine have been introduced. The 
newer area of antiplatelet agents has mainly been shaped by the ADP receptor antagonist 
clopidogrel since it has been approved by the FDA in 1997 and received extended approval 
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in 2002 for primary cardiovascular prevention. These approvals were later confirmed by the 
European drug authorities. The inhibitory effect of clopidogrel and other antiplatelet agents 
can be quantified with in vitro assays (see Table 1). The historical standard has been set by a 
method that used light transmittance through platelet rich plasma after inducing platelet 
aggregation with arachidonic acid, ADP, collagen and other activators [8]. In the past years, 
new assays to measure the effects of antiplatelet medication have become commercially 
available. 
Table 1. Commercially available assays to measure in vitro effects of aspirin and clopidogrel, 
modified from [9]. 
Assay Measure Sample 
Light transmission assay 
(LTA) 
Decline of light transmittance 
when platelet aggregation is 
induced by activators 
Platelet rich plasma 
Platelet count (conventional 
hematology analyser) 
Platelet count after induction of 
aggregation Whole blood 
Impedance aggregometry 
MULTIPLATE® 
Impedance between electrodes 
after addition of platelet 
aggregation inducers 
Whole blood 
PFA-100® (Siemens) 
Time until the blood sample flow 
through an activator-coated cell 
stops 
Whole blood 
Vasodilator stimulated 
phosphoprotein (VASP) flow 
cytometry assay 
Inhibition of P2Y12-mediated VASP 
phosphorylation Whole blood 
Ultegra® Rapid Platelet 
Function Assay / 
VerifyNow® 
Reduction of light transmittance by 
agglutination of fibrinogen-coated 
beads 
Whole blood 
Cone and Plate analyser 
(CPA) 
Platelet adhesion and aggregation 
under laminar flow with uniform 
high shear. 
Whole blood 
Thrombelastography (TEG) Prolonged clot formation Whole blood 
Thromboxan B2 (TXB2 
(Aspirin only) 
Decline in TXB2 formation  
(by inhibition of COX-1) Serum 
11-dehydrothromboxane B2 
(Aspirin only) 
Decline in TXB2 formation and 
excretion (by inhibition of COX-1) Urine 
 
An inter-individual variability of antiplatelet response has not only been described for 
clopidogrel, but could also been found to a lower degree in aspirin users [10]. Despite the 
proven efficacy of low-dose aspirin in cardiovascular prevention, there have always been 
patients who experienced clinical events despite antiplatelet therapy. Antiplatelet resistance 
with aspirin constituted a plausible background. Predictive in vitro tests and knowledge of 
associated factors are helpful for the identification and characterisation of antiplatelet 
resistance. 
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1.1.2. CONTRIBUTING FACTORS TO DRUG RESISTANCE 
Multiple factors can hinder the drug from inducing the expected response in the treated 
subject. The impact of different factors depends on the pharmacological properties of the 
drug, the route of administration, the therapeutic setting and the characteristics of the 
treated patients. The contributors to antiplatelet drug resistance have been systematically 
categorised into clinical, genetic and cellular factors [11]. Clinical factors involve inadequate 
prescribing, patient non-adherence, DDIs and intrinsic factors of the underlying disease. 
Genetic factors involve pharmacokinetic or pharmaco-dynamic polymorphisms, whereas 
cellular factors modulate response to treatment by receptor up- or down regulation and 
variation of enzyme activity. The contributing factors to resistance for the illustrative cases of 
aspirin (figure 1) and clopidogrel (figure 2) are depicted below. 
Figure 1. Proposed mechanisms of aspirin resistance (modified from [12]).  
GENERAL INTRODUCTION 
 24  
 
Figure 2. Proposed mechanisms of the response variability with clopidogrel (adapted from 
[13]). GP indicates glycoprotein. 
 
1.2. PHARMACOLOGICAL BIOMARKERS 
The introduction of the term “pharmacological biomarker” in 2008 in the MeSH terminology 
reflected the ongoing trend towards biomarker-based pharmacological concepts in the light 
of drug treatment personalisation. According to the MeSH definition, the term 
“pharmacological biomarker” refers to a “measurable biological parameter that serves for 
drug development, safety and dosing (drug monitoring)”. Biological markers or, more 
commonly, biomarkers are “quantifiable biological parameters which serve as health- and 
physiology-related assessments, such as disease risk, (…), environmental exposure and its 
effects …”[14]. 
Some biomarkers like Her-2/neu (overexpression in breast cancer associated with response 
to trastuzumab), HLA-B*51 (abacavir hypersensitivity) and HLA-A*3101 (carbamazepine 
toxicity) successfully translated from basic science into clinical routine. They help to predict 
safety and efficacy of the application of specific drugs in distinct patients and thus select the 
right treatment for each patient [15-17]. Additionally, pharmacological biomarkers for the 
phenotypical assessment of treatment response may help to optimize dosing and thus 
contribute to the personalisation of the therapy. 
The requirements concerning pharmacological biomarkers have been reviewed by Puntmann 
[18]. Examples of reliable and clinical biomarkers in general medicine are rare. Low-density 
lipoprotein cholesterol (LDL-C) to evaluate effectiveness of lipid lowering treatment with 
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statins is one of the most popular examples. In vitro platelet inhibition induced by antiplatelet 
drugs is another example of a biomarker that could be used for the evaluation of response in 
clinical practice. Historically, the inhibitory effects of aspirin and clopidogrel have not been 
routinely monitored. In the meantime, many studies have underlined the clinically predictive 
value of test results obtained with more recently introduced platelet aggregation assays [19-
21]. Many questions, especially regarding the standardisation of antiplatelet test results 
remained. However, pharmacological biomarkers have the potential to play an important role 
in the personalisation of antiplatelet therapy because of their ability to provide a rational basis 
in response-guided interventions [22]. 
1.3. PERSONALISED MEDICINE 
The aim of personalised medicine is to optimize effectiveness and to reduce toxicity of the 
treatment by tailoring a patients’ pharmacotherapy to individual factors that are known to 
influence the response to treatment. There is no consensus definition of personalised 
medicine, and experts in the field summarise a diversity of concepts under the term [23]. In 
a narrow sense, personalised medicine refers to pharmaco-genetic predictors of treatment 
response. Given the many clinical factors that interfere with the prediction of response and 
toxicity from genetic factors, personalised medicine should integrate clinical factors in order 
to bring out the true predictive power of a biomarker in a patient cohort. The patients’ clinical 
background as well as his perception of the disease and its treatment result in a large 
variation of subjective and objective adherence parameters and, accordingly, to a 
considerable variability of drug exposure. Subsequently, patient adherence is an important 
measure to be recorded and analysed to reach further advances in truly personalised 
medicine. The logical consequence for this thesis was to combine the assessment of 
pharmacological biomarkers with the objective measurement of multidrug adherence. 
1.4. ADHERENCE 
According to a new taxonomy introduced by Vrijens et al., “adherence to medications is the 
process by which patients take their medication as prescribed and which is further divided 
into three phases: initiation, implementation and discontinuation” [24]. Initiation and 
discontinuation of treatment are described as “inherently discontinuous actions, whereas 
implementation of the dosing regimen is continuous”, which “precludes a single, 
quantitatively useful parameter to cover all three” [24]. In the context of this thesis, the 
focus lies on on-going long-term therapies to be traced over a relatively short time period. 
Thus we deal mainly with methods to measure and report data on the implementation of the 
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drug therapy. This is mostly done by comparing the two time-series of the prescribed dosing 
regimen and the patient’s drug dosing history. Other summary parameters which were 
mainly applied in this thesis describe the intake times, dose-to-dose intervals and the intra-
individual variation of drug intake [25]. Adherence has been shown to be an important 
independent predictor of therapeutic efficacy on cardiovascular outcomes [26]. At least ten 
types of non-adherence are known, and all of them are associated with specific risks of 
adverse outcomes, either by the absence of the drug effect or by rebound effects due to 
drug withdrawal. 
Taking Adherence and Timing Adherence 
Reported adherence in conventional studies relies basically on taking adherence, which can 
be calculated from various measures, but mostly rely i) on pill counts or ii) on the medication 
possession ratio and iii) days covered based on prescription refill data [27]. These measures 
may be reliable for some situations, but are likely to mostly over-, but sometimes 
underestimate adherence. Today, a genuine, but pharmacologically naïve cut-off of 80% is 
often used to interpret data on taking adherence [28]. Data on timing adherence of all oral 
solid drugs will allow a more sophisticated interpretation of adherence data which involves 
the pharmacological properties of a drug. 
However, the focus of this thesis lies in the precise assessment of timing adherence. Timing 
adherence should be interpreted in the light of the specific requirements of the prescribed 
drug. The pharmacological properties of a drug define its forgiveness and thus the 
requirements regarding the precision in the execution of a therapy plan. Measuring timing 
adherence is essential to explore whether the patients intake characteristics fulfil the 
requirements of the prescribed regimen. Relevant deviations in timing adherence would 
translate into changes of biomarker measurements. The parallel measurement of timing 
adherence and pharmacological biomarkers is thus helpful to estimate tolerable deviations of 
timing adherence. Such estimations based on adherence and biomarker data would 
represent a step towards operational definitions for the implementation of a dosing regimen. 
Various authors claimed for disease- and drug-specific definitions that indicate clinically 
relevant deviations from the prescribed medication regimen [29-31]. 
Intentional and Unintentional Non-Adherence 
Intentional non-adherence results from the patients’ decision not to take medication or to 
take it in a way that differs from the recommendations [32]. Unintentional non-adherence 
occurs when patients are prevented from implementing their intention to take the 
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medication as prescribed by factors beyond their control, such as forgetfulness, poor 
comprehension (e.g. of the drug regimen), or physical inability to manage the medication. 
The two related types of behaviour may result in different pattern of objectively measured 
non-adherence, but are typically reflected by differing subjective measures of adherence. 
Objective Measures for Adherence Assessment 
A multitude of methods has been introduced for the objective measurement of adherence. 
For example, digoxin and phenobarbital in sub-pharmacological doses have been used as 
tracers. Despite their ability to precisely quantify a certain measure (e.g. drug concentration), 
there are drawbacks for the interpretation. Drug or tracer concentrations are not capable to 
give information about the dosing history and are generally not suitable to detect white coat 
adherence. Thus, the diverse methods differ in their ability to reflect the different forms of 
non-adherence. 
Electronic adherence assessment is an indirect objective measure of adherence. First data 
with the Medication Electronic Monitoring System (MEMS®) have been reported over 20 
years ago [33]. MEMS® was mainly employed in clinical trials and allowed insights into 
timing adherence characteristics of single drugs and laid the fundamentals for the 
understanding of drug effectiveness in the ambulatory setting. Specific studies with such 
adherence assessment have allowed unmasking the impact of non-adherence on 
effectiveness with antihypertensive drugs [34]. Statistical considerations on adherence as a 
control variable in multivariate analysis of drug effectiveness have become necessary, 
because the stringent data clarified that 100% adherence is a presumption that generally 
overestimates actual frequency of drug intake. Any finding regarding drug efficacy and safety 
may be diluted by an unknown contribution of non-adherence. 
In the past years, several companies have developed commercially available electronic 
devices to monitor and enhance patient adherence. Beside the simple registration of a time 
stamp from an event that is associated with drug adherence (e.g. cap removing, blister 
opening), they give feedback and use modern communication technologies in order to help 
patients to execute their therapy plan in concordance with their prescriptions. 
Polymedication Electronic Monitoring System (POEMS) 
Technological progress allowed imprinting electrically conductive ink onto polymer foils. The 
first clinical experience with this technique has been collected when mapping electronic 
circuitries on the backside of a commercial drug blister, which allowed tracking adherence 
with an oral anticoagulant without the need to remove the drug from its primary packaging 
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[35]. Further development in the context of this thesis allowed adapting the technology to a 
weekly multidrug blister pack (Pharmis®, Pharmis GmbH, Beinwil am See, Switzerland). This 
allowed monitoring adherence with the entire oral solid medication of a patient. Beside 
taking and timing adherence, the exposure to drug drug interactions can be measured. In the 
context of drug resistance and the assessment of contributing factors, this tool is essential 
for the quantification of clinical factors as outlined below. Otherwise, only potential factors 
instead of actual exposure would be measured. 
Subjective Measures of Adherence 
Subjective measures to assess adherence have been developed i) to identify patients at risk 
for non-adherence and ii) to characterise the personal background of non-adherence 
(intentional, non-intentional, patient beliefs and concerns). Subjective methods are relatively 
easy to perform and are cheap in comparison to objective methods, but are affected by 
recall bias. Furthermore, results can be affected by patients who give socially desirable 
answers. Two established questionnaires were used in the core projects (projects B, C, D) of 
this thesis: 
x The Beliefs about Medicines Questionnaire (BMQ) was developed by Horne and 
validated in various clinical settings [36]. In brief, it is based on the concept that the 
patients’ adherence is the result of his view of the necessities and concerns of the 
drug therapy. Sub-scores for necessities and concerns can be calculated, while the 
BMQ differential score integrates both measures. 
x The Morisky Medication Adherence Scale (MMAS-8) has proved to predict adherence 
in outpatients [37]. The MMAS-8 score is calculated from the patients’ answers to 8 
questions related to adherence, with lower scores indicating a higher risk of non-
adherence. 
1.5. SUMMARY OF RATIONALE AND APPROACH 
Drug resistance is characterised by the failure of a drug to produce the expected biomarker 
response in the treated patient. Resistant patients can thus be identified by a relatively 
simple measure in therapies where biomarkers exist that reflect the drug effect. Biomarker 
target attainment rates in cross-sectional studies are convenient to give an estimate on the 
burden of drug resistance with the respective treatment. 
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In a first retrospective study of unmet biomarker targets in cardiovascular risk patients 
treated with antihypertensives and lipid lowering drugs, we aimed at estimating the 
approximate rate of drug resistance with cardiovascular medication in an ambulatory setting. 
The following project on antiplatelet resistance represented the core study in the framework 
of this thesis. Its objective was to go beyond the surface of resistance and to assess the 
impact of the multiple presumed factors to drug resistance, thereby including prospective 
electronical adherence-monitoring to all oral solid drugs. Very recently, multidrug adherence 
monitoring with POEMS was developed which allows to precisely assessing adherence and 
exposure to DDI, two important clinical factors. Additionally, adherence monitoring with 
POEMS allows calculating summary statistics of timing adherence as a measure of 
implementation of the drug regimen. 
In a sub-study, we wanted to explore associations between the temporal pattern of 
multidrug adherence and biomarker response, which is a representative measure of the 
potential clinical consequences of the variability of drug exposure in daily life. Variations in 
timing of drug intake are unlikely to result in clinical consequences as long as they do not 
exceed the forgiveness of a drug. However, the consequences of prolonged dosing intervals 
are often not exactly known. Package inserts are generally lacking recommendations for the 
prevention of clinical consequences of deviations in drug execution. 
Finally, we introduced adherence monitoring to oral medication as an independent variable in 
a proposal for a study to compare effectiveness with oral vs. intramuscular vitamin B12. 
Analogous to in vitro platelet aggregation, lipid profiles and blood pressure in the foregoing 
studies with antiplatelet drugs, lipid lowering drugs and antihypertensives, vitamin B12 
associated biomarkers should be used as outcome measures of the execution of the oral 
vitamin B12 substitution. 
In summary, the aim of this thesis was to develop a new approach for the investigation of 
drug resistance, where adherence with oral drugs and actual exposure to DDIs should be 
considered as outcome predictors. For the prospective studies that were designed during 
this thesis, we combined the polymedication electronic monitoring system (POEMS) with 
biomarker assessments. First, this new approach allowed setting up a study to investigate 
intake characteristics of cardiovascular risk patients and possible associations with 
intermediate outcomes in lipid lowering therapy. Secondly, antiplatelet resistance with 
aspirin and clopidogrel could be studied with the precise assessment of adherence. Third, 
this approach served to develop the proposal for a study on the effectiveness of oral vs. 
intramuscular vitamin B12 supplementation in primary care. 
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1.6. OVERVIEW OF PROJECTS 
A. Prevalence of Unreached Biomarker Targets 
The effects of treatment with lipid lowering drugs on LDL-C levels and 
antihypertensive drugs on blood pressure can easily be monitored. For both 
biomarkers, well established therapeutic target levels exist. In a population-based 
cross sectional study, the percentage of patients not reaching their respective target 
levels was quantified, which may serve for estimating the incidence of drug 
resistance. 
x Walter, P., Messerli, M., et al., Prevalence of Unreached Biomarker Targets 
Under Antihypertensive and Lipid Modifying Therapy in Community Pharmacies in 
Switzerland. Internal work report. 
 
B. Development of a Study Design to Investigate Antiplatelet Drug Resistance  
A designated technology to assess multidrug adherence monitoring and adequate 
biomarkers to measure the response to treatment are the cornerstones of a clinical 
study to assess factors to antiplatelet resistance with aspirin and clopidogrel. This 
design allows to study the impact of non-adherence, exposure to DDI and other 
clinical (e.g. diabetes mellitus, inflammation) or pharmaco-genetic (e.g. CYP2C19 
polymorphisms) contributors. 
x Walter, P., Tsakiris, D.A., et al., Fundamental Progress in Investigating Drug 
Resistance with Electronic Multidrug Compliance Monitoring (e-MCM). J Patient 
Comp 2011;1(2):42-47. 
 
C. Exploring Associations between Objectively Measured Adherence and 
Biomarker Response in Lipid Lowering Therapy 
Project C1: Multidrug adherence monitoring allowed to precisely measuring various 
objective adherence parameters. Objective adherence parameters are likely to be 
influenced by subjective beliefs about the medication. On the other hand, objectively 
measured adherence parameters may have an effect on biomarker response. 
Therapy with lipid lowering drugs can serve as an example, where the clinically 
predictive biomarker LDL-C may be influenced by regular drug intake. In project C2, 
we report on an exemplary case in which irrational timing adherence was elucidated 
by multidrug adherence monitoring. 
x C1: Walter, P., Arnet, I., et al., Pattern of Timing Adherence Could Guide 
Recommendations for Personalized Intake Schedules. J Pers Med 2012;2(4):267-
276. 
x C2: Arnet, I., Walter, P.N., Hersberger, K.E., Polymedication Electronic Monitoring 
System (POEMS) – A New Technology for Measuring Adherence. Frontiers in 
Pharmacology 2013;4:1-6. 
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D. Antiplatelet Drug Resistance in Outpatients With Monitored Adherence 
The debate on antiplatelet resistance with aspirin and clopidogrel is controversial. 
Additional to other clinical, cellular and genetic contributors, non-adherence may well 
be a part of the difficulty to attain the expected inhibition of in vitro platelet 
aggregation in outpatients. In a prospective study on antiplatelet resistance that was 
carried out according to the design elaborated in project B, we measured multidrug 
adherence and other presumed contributors to analyse their impact on resistance. 
x Walter, P., Tsakiris, D.A., et al., Antiplatelet Resistance n Outpatients with 
Monitored Adherence. Thromb Haemost (submitted). 
 
E. Response to Vitamin B12 Substitution 
Commonly, vitamin B12 deficiency is treated with intramuscular injections in 
Switzerland. This study is designed to confirm the non-inferiority of oral high dose 
supplementation of vitamin B12. Adherence with the oral substitution and the 
patients’ acceptance of the two routes of administration are additional aims that will 
be addressed by this study. 
x Walter, P., Jeger, C., et al., Acceptance and Biomarker Response with Oral vs. 
Intramuscular Supplementation of Vitamin B12 in Primary Care. Study proposal. 
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Introduction 
The use of lipid modifying therapy (LMT) and antihypertensive therapy (AHT) for the 
modification of cardiovascular risk factors is widespread. Both LMT and AHT are established 
in primary and secondary prevention of cardiovascular events. LMT offers a 25-30% 
reduction of the relative cardiovascular risk in most of the large randomised trials [38]. The 
expected reduction of systolic blood pressure (SBP) varies between the classes of 
antihypertensive drugs, but is similar for diastolic blood pressure (DBP) [39]. The relative 
cardiovascular risk reduction with antihypertensives varies considerably between primary 
prevention and patients with specific risks, but has recently been questioned for primary 
prevention [40]. However, the effect of LMT and AHT is reflected by reductions in low 
density lipoprotein cholesterol (LDL-C) and by SBP and DBP. In Switzerland, 
recommendations for the use of LMT mainly rely on the European Society of Cardiology 
(ESC) and on the International Arteriosclerosis Society (IAS) guidelines [41]. According to 
IAS, LDL-C values in LMT should be lowered to 3.4 mmol/l (moderately elevated risk 
categories) and 2.6 mmol/l (high risk and manifest arteriosclerosis) [41]. Blood pressure 
targets for antihypertensive therapy are 140/90 mm or 130/85 mm Hg for patients with 
diabetes mellitus [42]. However, a substantial proportion of the treated patients does not 
reach these biomarker targets and is thus at risk not to take full advantage of the prescribed 
therapy [4, 43]. The prevalence of resistant hypertension is unknown, but estimates from 
clinical trials have enumerated resistance rates to 20-30% [2]. Target attainment failure in 
LMT and AHT is attributed to various genetic and clinical factors [44, 45]. Non-adherence is 
presumably a major clinical contributor with reported double-digit non-adherence rates for 
LMT in both primary and secondary prevention [46]. Community pharmacists are in an 
excellent position to address factors that are associated with a lack of target achievement, 
such as non-adherence, unfavourable lifestyle and nutrition, drug drug interactions (DDI), 
incorrect dosing, and pharmaco-genetic contributors. Pharmacological biomarkers could help 
to identify patients who can profit from pharmaceutical care interventions. Our aim is to 
describe the prevalence of patients not on target with AHT and LMT. 
Methods 
The data for this sub-analysis were obtained from a community pharmacy based screening 
program for cardiovascular risk factors (Herzcheck® campaign) in Switzerland. The collection 
of data involved blood chemistry using capillary blood samples, blood pressure (BP), body 
mass index, and lifestyle factors of participants. Blood chemistry analysis included total 
cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglycerides (TG). 
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Patients with a prescription for AHT were labelled as “not on target” if their BP was  
140/90 mmHg (SBP/DBP) or  150 mmHg (isolated SBP), while LDL-C > 3.4 mmol/l was the 
respective criterion for patients with LMT. 
Patients with LMT were further labelled as “optimisable” if LDL-C was  3.4 mmol/l, but 
HDL-C was < 1.0 mmol/l, TC/HDLC > 5, and/or TG > 2.5 mmol/l. 
Results 
From a total of 4380 screened subjects, 863 (19.7%) were selected because they had a 
prescription for either AHT (n=537, 12.3%; age=67.9±10.3 years; 68.5% women), LMT 
(n=157, 3.6%; age=64.9±10.1 years; 56.7% women), or both (n=169, 3.9%; 68.6 ±9.9 
years; 55.6% females). 
Of 706 patients with AHT, 256 (36.3%) were not on target because they violated either the 
systolic/diastolic (n=165, 23.4%) or the isolated systolic BP (n=91, 12.9%) criterion. LMT 
was prescribed in 326 patients, of which 84 (25.8%) were not on target, while the 
management was optimisable in another 85 patients (26.1%). 
Male patients with higher age were more likely not to be on target with their AHT, while 
female patients with younger age were overrepresented in the group of patients that did not 
reach their target in LMT (see table 1). Patients who were treated both with LMT and AHT 
were more likely to reach their LDL-C and AHT targets. 
Table 1. Patients on target and not on target with their AHT and LMT  (*=mean difference 
and 95% CI instead of OR) 
Antihypertensive therapy (AHT), N=706 
 Not on target N=256 
On target  
N=450 OR [95% CI] p-value 
Age 69.8 ± 9.7 y 67.0 ± 10.3 y -2.8 y [-1.2- -4.3]* <0.005 
Women 151 (59.0%) 311 (69.1%) 1.56 [1.13-2.14] 0.007 
Cigarette 
smoking 
15 (5.9%) 30 (6.2%) 0.94 [0.49 -1.79] 0.846 
Concomitant 
use of LMT 49 (20.3%) 120 (25.7%) 1.54 [1.06-2.24] 0.024 
Lipid modifying therapy (LMT), N=326 
 
Not on target On target + 
optimisable 
N=242 
OR [95% CI] p-value 
N=84 
Age 64.0±11.4 y 67.8±9.6 y 3.72 y [6.2-1.2]* <0.005 
Women 58 (69.0%) 125 (51.7%) 0.48 [0.28-0.81] 0.006 
Cigarette 
smoking 
8 (9.5%) 21 (6.4%) 1.11 [0.47-2.61] 0.814 
Concomitant 
use of AHT 34 (40.5%) 135 (55.8%) 1.86 [1.12-3.07] 0.016 
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Discussion  
In approximately one third (36.3%) of the AHT and in one quarter of LMT (25.8%), patients 
failed to reach the biomarker targets. BP and LDL-C represent established surrogate 
outcomes of the drugs’ effect. A gap between the measured biomarker levels and target 
values according to the guidelines indicates suboptimal therapy effectiveness. However, in 
the absence of access to clinical data of the patients, the biomarker targets in this study 
were defined as cut-offs irrespective whether patients took the drugs for primary or 
secondary prevention or whether they had diabetes mellitus. A multi-center survey in the 
United States with 4888 patients with LMT found an overall rate of 38% non-achievers of 
their respective target LDL-C according to the National Cholesterol Education Program 
(NCEP) guidelines,  but the targets were stratified for the patients cardiovascular risk [47]. In 
a study performed in a U.S. managed care organization, adherence with AHT and LMT as 
measured by prescription refill data was found to decline sharply following treatment 
initiation and reached only 35.8% after 12 months [48]. Concomitant initiation of AHT and 
LMT was independently associated with better adherence in this U.S. study. Better 
adherence may thus be the background of the higher likelihood of target achievement that 
was observed in our study when patients were concomitantly treated with LMT and AHT. 
Thus, non-adherence is reasonably a plausible major contributor to the large proportion of 
patients who did not achieve their targets in our study. 
Strengths and Limitations 
Studying target attainment rates in a pre-existing database of patients with AHT and LMT is 
a simple approach that allowed involving a relatively large patient sample with limited 
resources. On the other hand, a retrospective analysis is inherently flawed by limited data 
quality. We had neither reliable clinical or medication data of the patients, nor were we 
informed about individual therapeutic targets of the patients. Thus it was not possible to 
evaluate whether the patients received adequate treatments. The biomarker cut-offs that 
were used to define target attainment have been set at relatively high levels to increase 
specificity and thus resulted in conservative estimates on resistance to LMT and AHT. Data 
on prescribed drugs and adherence would be necessary to distinguish between different 
factors responsible for the failure to attain biomarker targets. The patient data was collected 
during a health check campaign without distinct inclusion or exclusion criteria, thus the 
sampling might have been subject to selection and bias. 
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Conclusion 
This study confirmed that a substantial rate of patients fails to attain the biomarker targets in 
lipid modifying and antihypertensive therapy. Little is known on the differential impact of 
presumed contributing factors (e.g. pharmaco-genetics, DDI, non-adherence) on the failure 
to reach the target levels. Remarkably, concomitant antihypertensive and lipid modifying 
therapy seems to result in better target attainment, presumably due to better adherence. 
This observation needs further investigation. 
Knowledge of factors that are associated with a lack of target attainment is essential and can 
put healthcare professionals in an ideal position to plan and perform interventions to help 
patients to take full advantage of the prescribed therapy. Prospective studies with electronic 
multidrug adherence monitoring are required to disclose the impact of these presumed 
factors. 
References 
See general references section.  
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Abstract 
Background and Purpose 
Current definitions of drug resistance are shaped by the pharmacotherapeutic fields they 
occurred in. They usually mention various contributing factors and refer either to the clinical 
or the biomarker level. Particular attention has been attracted by antiplatelet resistance, a 
phenomenon with clinical, cellular and pharmacogenetical contributors. However, the impact 
of every single factor to antiplatelet resistance in outpatients under prescribed antiplatelet 
therapy has not been comprehensively evaluated so far, neither has the temporal pattern of 
drug intake been studied as a possible contributor. 
Methods 
We propose generally applicable definitions of drug resistance, therapy failure and a 
classification of contributing factors to drug resistance. We introduce a study design with the 
use of blisterpacks in a target population (i.e. patients with a prescription of antiplatelet 
drugs), filled with the entire oral medication regimen, and equipped with electronic multidrug 
compliance monitoring (e-MCM) allowing thus to evaluate in a stepwise way the impact of 
the contributing factors (e.g. potential drug-drug interactions, genetic polymorphism) on 
biomarker outcome (i.e. in vitro platelet aggregation), with proven intake of the polytherapy. 
Discussion and Conclusion 
Drug resistance should be judged with the knowledge of the contributing factors and in the 
context of a patient’s polytherapy under daily life conditions. The use of electronic multidrug 
compliance monitoring (e-MCM) allows the ruling out of non-compliance and the evaluation 
of the impact of potential drug-drug interactions on biomarker outcome. Pharmacogenetic 
testing may thus be restricted to those patients with a persistent lack of response, and the 
impact of the genotype may be interpreted within patients’ specific clinical context. An 
evidence-based optimisation of the therapy in case of insufficient biomarker response may 
thus be given, and the intervention can be stratified according to the identified contributing 
factors. The debate may then be opened on the clinical benefit and the cost-effectiveness of 
practices currently used to overcome insufficient effectiveness solely based on biomarker 
findings. 
Keywords: Compliance, drug resistance, electronic multidrug compliance monitoring, 
pharmacological biomarker. 
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Background 
The term “drug resistance” has emerged from antibiotic and anticancer therapy and has 
been discussed in many fields of pharmacotherapy, such as antihypertensive drugs [2], 
antiepileptics [3, 49], antidepressants [50], lipid modifying therapy [4] and antiplatelet 
medication [51-53].  
“Drug resistance” was introduced as a Medical Subject Heading (MeSH) in 1972 and refers 
to a “diminished or failed response of an organism, disease or tissue to the intended 
effectiveness of a chemical or drug”. This circumscription provides a short and global 
definition of the phenomenon, but does not specify the clinical context under which 
resistance is observed. Furthermore, the definition omits to mention if the effectiveness is 
measured on a clinical level (e.g. mortality) or on the surrogate marker level. 
The term “drug resistance” has further been shaped by various authors in the context of 
their specific field of interest. The different proposed definitions have some basic features in 
common, like the clinical relevance of drug resistance, its multifactorial aspect, and its 
detection through pharmacological biomarkers [2-4, 49-53], but no generally accepted 
concept of drug resistance has emerged. 
Antiplatelet Drug Therapy for the Investigation of Drug Resistance 
Dual antiplatelet therapy with aspirin and clopidogrel is a well-established regimen in the 
prevention of stent thrombosis [54], whereas aspirin has proved its efficacy in the primary 
and secondary prevention of cardiovascular and cerebrovascular events [6]. Up to 20% of 
patients experience recurrent cardiovascular events despite dual antiplatelet therapy after 
percutaneous coronary intervention [55]. These incidence rates have raised the question of 
antiplatelet drug resistance, which is characterised by persistent in vitro platelet aggregation.  
The term “antiplatelet resistance” describes “a phenomenon of measureable, persistent 
platelet activation that occurs in patients with prescribed therapeutic doses of aspirin” [56]. 
This definition is restricted to a biochemical phenomenon and includes any factor liable to 
compromise the biomarker outcome, including clinical factors that reduce drug exposure like 
non-compliance or poor absorption.  
Clopidogrel resistance received special attention and was differently named 
“nonresponsiveness” [57] or “variability in platelet response” [58]. The phenomenon has 
been associated with CYP2C19 loss-of-function genotype [59] and with drug-drug 
interactions affecting CYP2C19 and CYP3A4 metabolic capacity [60-62]. Further factors with 
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possible influence on platelet activity were described, like tobacco smoking [63], diabetes 
mellitus [64] and systemic inflammation with increased platelet turnover [65]. None of these 
factors emerged as the most likely cause for the unmet clinical outcome, but their effects on 
in vitro platelet aggregation are evident.  
Non-compliance must be generally suspected when patients under antiplatelet therapy do 
not display the expected in vitro platelet inhibition. Non-compliance has been described as a 
contributor of outstanding impact in aspirin therapy [66], with a prevalence of 22% in a 
cohort with manifest coronary artery disease and stroke [67]. However, when aggregation is 
inhibited, this means that an appropriate amount of the prescribed drug has been taken to 
produce the pharmacological effect, not that the prescribed regimen has been adhered to 
[68]. The contribution of non-compliant behaviour to antiplatelet resistance in outpatients 
under prescribed antiplatelet therapy has not been evaluated so far. 
Definition of and Contributing Factors to Drug Resistance 
“The absence of the expected biomarker response under (adequately) prescribed therapy (in 
correctly diagnosed patients)” may represent the cornerstone of a general definition of drug 
resistance. Consequently, we support that an unfavourable clinical outcome should be 
addressed as “treatment failure” [5] while “drug resistance” should be reserved for 
therapies whose efficacy can be evaluated with pharmacological biomarkers. 
When a patient fails to respond adequately to a prescribed treatment, either on a clinical or 
on a biomarker level, the physician must distinguish among different causes of variability 
(pharmacological, behavioural, biological). Often, a combination of factors has produced the 
suboptimal results. Given the above definition of drug resistance, the contributing factors 
can be classified into clinical, genetic and cellular factors (Table 1), as already proposed for 
antiplatelet resistance [69]. Each single factor may negatively influence the biomarker 
response, and the ensuing impact depends on the taken drug. 
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Table 1. Contributing factors to drug resistance, with specific examples for antiplatelet drug 
resistance 
Factors contributing to drug resistance  
Factors contributing to antiplatelet drug 
resistance (aspirin and/or clopidogrel) [5, 69] 
Clinical factors  
Prescription Failure to prescribe; Underdosing 
Patient non-compliance Mostly delayed or omitted doses 
Poor absorbance  
Drug-drug interactions 
Interaction with ibuprofene (aspirin); 
Interaction with PPIs and statins 
(clopidogrel) 
Lifestyle factors Tobacco smoking; Elevated body mass index 
Comorbidity 
Diabetes mellitus; 
Acute coronary syndrome; 
Systemic inflammation 
Genetic factors  
Pharmacokinetic Polymorphisms of MDR1 and CYP isoforms 
Pharmacodynamic Polymorphisms of P2Y12 and GPIIb/IIIa  
Cellular factors  
Cell turnover Increased platelet turnover 
Adaptive cellular mechanisms Increased ADP exposure 
Up-/down-regulation of cell metabolism Up-regulation of ADP-mediated pathways 
In summary, we promote the comprehensive assessment of drug resistance with the 
evaluation of all contributing factors. To this purpose, we propose a study design with the 
implementation of a new compliance monitoring technology, using the field of antiplatelet 
resistance as a model. 
Aims of the Study 
The aims of the study of which the design is presented in this article are to identify 
resistance to antiplatelet therapy in outpatients with a prescription of antiplatelet agents, and 
to assess all factors that compromise the biomarker response, i.e. the platelet aggregation.  
Methods 
Blisterpack and Compliance Measurement Technology 
We chose a commercially available weekly blisterpack with 7x4 compartments (Pharmis 
GmbH, Beinwil a.S., Switzerland), filled with the entire oral medication regimen of the 
patient (Rx and OTC drugs). The back of the blisterpack is covered with a clear, self-adhering 
polymer foil (provided by ECCT B.V. Eindhoven, NL) with loops of conductive wires and 
connected to electronic components (Fig. 1). The attached microchip measures the electrical 
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resistance, and records the time of its changes when a loop is broken, i.e. when a cavity is 
emptied. The data is transferred with a wireless communication device (near field 
communication) to a web-based database.  
 
Figure 1. Electronic multidrug compliance monitoring (e-MCM) system 
This electronic multidrug compliance monitoring (e-MCM) system enables the monitoring of 
the entire pharmacotherapy, and thus assessment of compliance behaviour and drug-drug 
interactions. 
Recruitment and Inclusion Criteria 
Patients are recruited at their local general practitioners (GP) surgeries during a routine 
consultation. Inclusion criteria are the prescription for aspirin and/or clopidogrel for the 
prevention of primary or secondary atherothrombotic events (cardiovascular, stent 
thrombosis or cerebrovascular event), or for the treatment of peripheral arterial occlusive 
disease (PAOD), and the patient’s agreement to get a weekly blisterpack with electronics (e-
MCM) prefilled with all orally administered drugs and to leave all extra drugs at the study 
centre. Exclusion criteria are acute cardiac symptoms, residence in a care home or receiving 
home care, and lack of discernment to manage one’s own pharmacotherapy. The use of a 
pill organiser is not an exclusion criterion. 
  
ADHERENCE AND BIOMARKERS 
 45  
Biomarkers for Antiplatelet Therapy 
Historically, platelet aggregation in platelet-rich plasma was the method of choice to assess 
in vitro platelet activity [8]. In recent years, new assays have become commercially available. 
Raising evidence supports the introduction of multiple electrode aggregometry (MEA, 
Dynabyte, Munich, Germany) for the measurement of platelet aggregation and the prediction 
of the clinical outcome [20]. In the described study design, MEA is applied to measure in 
vitro platelet aggregation. The MEA instrument allows two ways to express the AUC: as 
BSCJUSBSZBHHSFHBUJPOVOJUT	"6nNJO
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U. The cut-off value was set at 54 U [70]. 
Study Plan and Stepwise Assessment of Contributing Factors 
At visit 1, demographic data including smoking status, educational level and social 
background is collected; baseline laboratory data including platelet aggregation is measured, 
and the individualised blisterpack for one week is delivered. Patients are informed that their 
drug intake will be electronically monitored, and advised to take their drugs as they were 
instructed in usual care. Patients’ extra drugs are stored at the study centre during 
participation, thus rendering parallel drug consumption impossible. 
At visit 2, one week later, in vitro platelet aggregation is measured and serves to 
dichotomise the study cohort into subjects with a) sufficient and b) insufficient platelet 
inhibition. The latter group will get another week of compliance-monitored therapy, with an 
additional direct observation (DOT, directly observed therapy) of the doses containing the 
antiplatelet drug on five of seven days.  
The assessment of drug-drug interactions and pharmacogenetic polymorphisms is 
performed in all patients. 
Sample Size Estimation 
The incidence of antiplatelet resistance in patients with a prescription for aspirin and/or 
clopidogrel varies widely (8 - 45%) [56]. For circumstances as defined in our study, an 
incidence of 20-30% seems reasonable. The presence of main contributing factors in the 
general population is assumed to be 15% for the loss-of-function genotype (g), 60% for 
drug-drug interactions (d), and 20% for comorbidities (c). Thus, the codes of the different 
patient groups and the rates of non-responders would be g0d0c0 (2%), g0d0c1 (60%), 
g0d1c0 (15%), g0d1c1 (65%), g1d0c0 (55%), g1d0c1 (75%), g1d1c0 (75%), g1d1c1 (90%), 
with 1 if the factor is present, and 0 if the factor is absent. The primary analysis should 
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demonstrate that the main contributing factors have the expected influence on non-
response. A Monte Carlo simulation with adjusted sampling for the estimated overall 
incidence of non-response resulted in a required total of 493 evaluable patients to achieve a 
power of 80% as for the primary analysis. 
Expected Results 
Baseline platelet aggregation at visit 1 mirrors the effectiveness of a patient’s polytherapy, 
i.e. drug efficacy under daily life conditions. We expect the values after one week to show 
an improved platelet inhibition, independently of the baseline value (and very likely because 
of the Hawthorne effect), and to draw conclusions on the optimal temporal pattern of drug 
intake on biomarker outcome with antiplatelet drugs. 
With proven compliance by means of e-MCM, we will be able to quantify the clinical, genetic 
and cellular factors other than non-compliance in patients with insufficient platelet inhibition 
under aspirin and/or clopidogrel. With the tracking of the entire pharmacotherapy, we will be 
able to evaluate the impact of drug-drug interaction on the biomarker response, and to make 
recommendations for action when platelet inhibition is insufficient. We expect differences 
between both groups (aspirin and clopidogrel) in frequency rates, with a greater importance 
of pharmacogenetic polymorphisms and drug-drug interactions under clopidogrel therapy. 
Non-compliance is assumed to have a similar impact on in vitro platelet inhibition for both 
antiplatelet drugs.  
Discussion and Conclusion 
The use of electronic multidrug compliance monitoring (e-MCM) for the assessment of drug 
resistance allows us to rule out non-compliance and to evaluate the impact of potential drug-
drug interactions on biomarker outcome. Pharmacogenetic testing may be restricted to 
those patients with a persistent lack of response. An evidence-based optimisation of the 
therapy in case of insufficient biomarker response is thus given, and the intervention can be 
stratified according to the identified contributing factors. The efficacy of the intervention can 
then be estimated with the biomarker outcome. In essence, the switch to another drug can 
be proposed only in case of proven inefficacy (genetic polymorphism, comorbidity, inevitable 
interaction). Our stepwise approach to identify and assess drug resistance in individual 
patients is applicable to many therapeutic settings, like treatment of dyslipidemia, 
hypertension, osteoporosis, and congestive heart failure. 
To our knowledge, prospective compliance monitoring in patients with antiplatelet drug 
resistance has not been evaluated so far; neither has the applicability of in vitro platelet 
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monitoring with multiple electrode aggregation (MEA) in a primary care setting. Insufficiently 
lowered platelet aggregation with MEA is associated with an unfavourable clinical outcome 
and thus underlines the relevance of the finding. Stratified interventions may optimise safety 
and effectiveness of drug therapies under daily life conditions, and back up the utility of 
diagnostic strategies addressing drug resistance. Further studies are needed to evaluate the 
clinical benefit and cost-effectiveness of identifying and treating drug resistance in different 
population groups. 
Summary Points 
n We support a new definition of drug resistance and propose its attribution to an 
inadequate biomarker response to prescribed drugs. 
n Drug resistance is a phenomenon with multiple contributing factors on the clinical, 
genetic and cellular level. 
n Antiplatelet drug resistance can serve as a model for drug resistance. 
n The assessment of contributing factors must involve electronic multidrug compliance 
monitoring (e-MCM) to rule out non-compliance and to measure exposure to drug-
drug interactions. 
n More studies are needed to evaluate the clinical benefit and cost-effectiveness of 
identifying and treating drug resistance in different population groups. 
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Abstract 
Deviations in execution from the prescribed drug intake schedules (timing non adherence) 
are frequent and may pose a substantial risk for therapeutic failure. Simple methods to 
monitor timing adherence with multiple drugs are missing. A new technology, i.e., the 
polymedication electronic monitoring system (POEMS) attached to a multidrug punch card, 
was used in a clinical trial on outpatients with prescribed medicines for vascular risk 
reduction. The complete delineation of timing adherence allows for the calculation of 
objective adherence parameters and the linking of exposure with drug-drug interactions. A 
sub-analysis was performed on 68 patients, who were prescribed lipid lowering therapy. A 
smaller intake time variability of the lipid lowering drug was significantly associated with 
better levels of LDL-cholesterol, independently of the time of day. This finding may 
challenge current general recommendations for the timing of lipid lowering drugs’ intake and 
substantiate that inter-individual differences in timing adherence may contribute to response 
variability. Thus, objective parameters based on multidrug adherence monitoring should be 
considered as independent variables in personalized medicine. In clinical practice, 
personalized intake recommendations according to patients’ pattern of timing adherence 
may help to optimize the effectiveness of lipid lowering agents. 
 
Keywords: Compliance, adherence, time variability, electronic polymedication monitoring, 
lipid lowering agents 
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1. Introduction 
Patient non-adherence and shortcomings in timing adherence with prescribed drug regimen 
poses a substantial risk for therapeutic failure, regardless of the disease or patient 
characteristics [71].  
Non-adherence is the result of multiple factors that have been classified into five dimensions 
[72]. Therapy-related factors, such as co-medication, dosing frequency and intake schedules, 
are likely to affect the execution of the patients’ therapy plans. Numerous direct and indirect 
methods for adherence measurement have been described [73]. More than 20 years of 
research on electronic adherence monitoring revealed several patterns of adherence, 
however focusing only on single drugs [33, 74]. Electronic adherence monitoring proved to 
be the most sensitive method for adherence assessment and provided the best predictor of 
health outcomes [75, 76]. The recently introduced polymedication electronic adherence 
monitoring system (POEMS) allows for monitoring of the intake of all oral solid drugs [77]. 
The complete delineation of timing adherence with any of the prescribed oral solid drugs 
allows for assessing whether specific adherence parameters are associated with biomarker 
outcomes, which are predictive of effectiveness and toxicity. Taking non-adherence is often 
arbitrarily defined as 80% of doses taken, regardless of the drug, although the rationale for 
drug-specific and more sophisticated cut-offs could be deducted from pharmacokinetic and 
pharmacodynamic characteristics [28]. Continuous variables for timing adherence can be 
helpful to overcome this imprecision. Time variability of drug intake (tVAR) was introduced to 
describe intra-individual intake variation [25]. Except for oral contraceptives, little is known 
about the impacts of intake time deviation on drug effectiveness, and no advice can be 
retrieved from drug labels on what should be undertaken if time deviations or missed doses 
occur. Pharmacodynamic biomarkers as intermediate outcomes can help to study the 
tolerability of time deviations in the execution of the drug regimen [78]. Low density 
lipoprotein cholesterol (LDL-C) is a well-established biomarker that reflects the effectiveness 
of lipid lowering therapy with statins, and substantial gaps to LDL-C target achievement have 
been reported [47]. The impact of adherence patterns on LDL-C values was analyzed in the 
context of a prospective trial on antiplatelet resistance in which adherence was monitored 
with POEMS [79]. The results presented in this article describe the intake characteristics of 
an outpatient cohort, their association with the treatment schedule, subjective measures of 
adherence and biomarker response in lipid lowering therapy. 
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2. Methods 
The parent trial on antiplatelet resistance (ClinicalTrials.gov ID: NCT01039480) was approved 
by the cantonal ethics committee of Aargau, Switzerland and included patients with a 
prescription for aspirin and/or clopidogrel, recruited by general practitioners. Patients with a 
full set of data were included in the analysis, and sub-analysis concerned users of a lipid 
lowering drug (LLD). Levels of LDL-cholesterol (LDL-C) were used as surrogate outcome for 
therapeutic effectiveness. All the patients’ oral solid drugs were repacked into a multidrug 
punch card (Pharmis GmbH, Beinwil am See, Switzerland) with 7 × 4 units-of-use for seven 
days. The backside was covered with a polymer film, which registered the drug removal 
from each unit-of-use. The POEMS technology consists of imprinted electronic components 
that measure the electrical resistance and record the time of its changes when a loop is 
broken, i.e., when a cavity is emptied. The patients were advised to take their drugs at the 
time they were normally used to and to return the punch card upon their second visit after 
one week. Removal of drugs on demand was recorded, but not considered for analysis. 
Individual intake schemes were analyzed, regardless of the prescribed treatment schedules. 
The following parameters were derived from the electronic reports and calculated as 
follows: 
x (a) Time variability of drug intake (tVAR) according to equation (1) [25]. 
tVAR = 
σ หtik-median (i)หk
number of prescribed dosing days for subject i
 (1) 
x (b) Dose-to-dose intervals as the time difference between two consecutive removals.   
x (c) Weekend effects as the differences between objective adherence parameters on 
working days (Monday to Friday) and weekend days (Saturday and Sunday). 
Patients’ subjective adherence scores were obtained with the Morisky-8 (MMAS-8, score 0 
to 8) and the Beliefs about Medicines (BMQ) questionnaires [36, 37]. Subscores for BMQ 
necessity (score 5 to 25), BMQ concerns (score 5 to 25) and BMQ differential (score í20 to 
+20) were calculated according to the authors [36]. In brief, higher scores are associated 
with better adherence. 
Blood samples were analyzed with a Coulter® AcTDiff (Beckman Coulter Inc., Brea, CA, 
USA) for hematology and Cobas® 6000 (Roche Diagnostics Inc., Rotkreuz, Switzerland) for 
clinical chemistry. Target LDL-C levels were set at 3.4mmol/L and 2.6mmol/L for primary and 
secondary prevention, respectively. The lipid lowering potency of the prescribed drugs were 
classified in five groups according to equivalence dose tables in order to control for uneven 
distribution in the statistical analysis [80]. 
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Statistical Analysis 
Values are given as mean ± SD, median, quartiles and percentages where appropriate. 
Differences between patient groups were analyzed with unpaired t-Tests and the Mann-
Whitney U-test, where applicable. Time variables were treated as scaled variables; objective 
adherence parameters were calculated and compared in a bivariate model using the 
Spearman rank correlation. A one way ANOVA, followed by post hoc LSD test, was used to 
compare differences of mean intake times between days. Two-tailed p-values 0.05 were 
considered significant. 
3. Results 
3.1. Patient Characteristics 
The principal study, conducted between June 2010 and June 2011, was completed by 82 
patients. Full sets of data were obtained for 78 patients. The study sample (30.8% women, 
mean age 66 ± 10 years) consisted of 44 patients (56.4%) with a history of arteriovascular 
events, and 34 patients (43.6%) were prescribed antiplatelet agents for primary prevention. 
Patients were prescribed one to 13 (median: five) drugs for oral intake, to take once a day 
(32 patients, 41.0%), twice (35 patients, 44.9%), thrice (eight patients, 10.3%) or more than 
thrice daily (three patients, 3.8%) (see Table 1 for more details). Higher dosing frequencies 
correlated strongly with a higher number of prescribed drugs (R2 = 0.61; p < 0.001). 
Antihypertensives were prescribed in 63 patients (82.9%), and 15 patients (19.2%) had an 
antidiabetic co-medication. Sixty-eight patients (87.2%) received LLD and attained mean 
LDL-C values of 2.3 ± 0.6 mmol/L (primary prevention; target values <3.4 mmol/L) and 2.5 ± 
0.7 mmol/L (secondary prevention; target values <2.6 mmol/L). 
Table 1. Therapy plan characteristics for n = 78 patients with full sets of data.  
Dosing 
frequency 
Number of drugs Treatment schedule 
N % 
Median Range Morning Midday Evening At night 
1 × daily 3.5 1–7 
X    30 38.5 
 X   1 1.3 
   X 1 1.3 
2 × daily 5.0 2–11 
X  X  30 38.5 
X X   2 2.6 
X   X 2 2.6 
 X  X 1 1.3 
3 × daily 7.0 3–10 
X X X  5 6.4 
X X  X 3 3.8 
4 × daily 11.0 6–13 X X X X 3 3.8 
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The median MMAS-8 score was 8.0 (range 4.5–8.0) and indicates a high adherence; the 
maximum score was reached by 53 patients (67.9%). BMQ subscores revealed a high 
perception of necessity (median 20; range 6–25) and little concerns (median 8; range 5–20). 
Patients with secondary prevention had moderately higher MMAS-8 scores (7.7 ± 0.6 vs. 7.3 
± 0.9; p = 0.06) and significantly higher BMQ necessity subscores (20.4 ± 4.0 vs. 17.9 ± 4.2; 
p = 0.01) than patients with primary prevention. The BMQ concerns score did not differ 
between these groups. 
3.2. Objective Measures of Adherence 
The prescriptions of the 78 patients theoretically involved 962 drug removals to be executed 
during the study participation. All dispensed punch cards were returned at the final visit 
(100% return rate). Visual inspection performed by the investigator confirmed that all 
removals were executed, but 47 events were not recorded (4.9% missing data), and 30 
events could not be assigned to a drug removal even after a post hoc interview-based 
verification (3.1% implausible data) due to a deficiency in the recording technology.  
See Table 2 for the parameters describing the different intake times. Mean time variability 
was significantly lower in the morning than in the evening (34:16 min:s vs. 49:31 min:s; p = 
0.05). 
Table 2. Description of median intake time and time variability (tVAR) over three intake 
times for 78 patients. Parameters were calculated when at least three (median) or four 
(tVAR) records per intake time were available. 
 Morning Midday Evening 
 
Median 
[h:min] 
tVAR [min:s] 
Median 
[h:min] 
tVAR [min:s] 
Median 
[h:min] 
tVAR [min:s] 
N 73 72 10 10 39 37 
Mean 7:33 34:16 12:00 27:24 19:01 49:31 
SD 1:00 28:50 00:33 29:37 1:35 50:43 
Median 7:41 30:00 12:09 13:45 18:36 37:17 
IQR 
7:01–
8:14 
18:17– 
40:22 
11:56–
12:11 
11:00–
27:34 
18:05–
19:27 
19:43– 
52:51 
Range 
4:00–
9:23 
00:43–
228:45 
10:28–
12:35 
6:51–
103:26 
16:02–
23:26 
02:43–
250:34 
Of 46 patients with more than one intake daily (Table 1), 38 had schedules that allowed for 
the calculation of intervals between morning and evening (see Table 3). Additional doses 
(midday and/or at night) were prescribed in 10 patients. 
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Table 3. Intervals between doses (mean ± SD) for 35 patients with morning-evening 
schedules (data of three patients were excluded from the calculation due to incomplete 
pairs). 
Treatment schedule N Mean interval [h:min] 
Morning-Evening 35 11:38 ± 1:49 
X-0-X-0 25 11:48 ± 1:53 
X-X-X-0 5 11:33 ± 1:01 
X-0-X-X 2 10:10 ± 0:52 
X-X-X-X 3 11:23 ± 3:07 
Morning-Midday 8 4:32 ± 1:04 
Midday-Evening 7 6:33 ± 0:31 
 
3.3. Weekend-Effect 
Mean intake times were significantly delayed on Saturday and Sunday compared to working 
days (p < 0.001). Consequently, the weekend days contributed significantly more to the 
overall drug intake variation than the working days (23.5 ± 12.7% vs. 10.6 ± 5.1%; p < 
0.001). This effect was less pronounced in retired patients (N = 41; 30.0 ± 13.5%) than in 
working patients (N = 30; 18.4 ± 9.8%, p < 0.001), but was independently observed in both 
groups. In absolute numbers, the mean tVAR on working days was comparable in retired and 
working patients (22:48 ± 13:52 min:s vs. 22:23 ± 22:55 min:s, p = 0.92). 
Figure 1. Median intake times of the morning doses in retired (N = 41) and working (N = 
30) patients. Whiskers indicate the 1st and 3rd quartiles, respectively. 
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3.4. Socio-Demographic Factors 
Time variability over the entire week differed significantly between retired and working 
patients (25:59 ± 13:44 min:s vs. 45:28 ± 39:28 min:s, p = 0.012) due to the weekend effect 
mentioned above. A tendency towards higher precision in timing adherence was observed in 
women compared to men (24:53 ± 13:44 min:s vs. 38:39 ± 33:08 min:s, p = 0.060), while 
no significant differences were found when patients were grouped by social status, 
smoking, prevention, treatment schedule (once daily vs. more than once daily) and MMAS-8 
scores. Increased age correlated significantly with a more precise timing adherence 
(Spearman Rho = í0.382, p = 0.001).  
3.5. Treatment Scheme and Subjective Adherence 
The number of concomitant drugs and the dosing frequency were not associated with time 
variability of drug intake. Patients’ beliefs and concerns, summarized by the BMQ differential 
score, were in good agreement with subjective adherence reported by the MMAS-8 score 
(R2 = 0.376, p = 0.001). This correlation was mainly driven by the BMQ concerns sub-score, 
which significantly correlated with tVAR (R2 = 0.242, p = 0.04). 
3.6. Biomarker Response 
Of the 68 patients with LLD, 22 (32.4%) did not reach their target LDL-C values and had a 
lower timing precision of the LLD intake compared to the 46 patients (67.6%) who reached 
their target LDL-C values (tVAR = 67:44 ± 76:22 min:s vs. 28:05 ± 18:54 min:s, p = 0.011). A 
higher timing variation of the LLD intake correlated with higher LDL-C values (R2 = 0.323, p 
= 0.011). In parallel, patients with morning intake of the LLD had a tendency towards lower 
LDL-C values than patients with evening intake (2.3 ± 0.6mmol/L vs. 2.6 ± 0.7 mmol/L, p = 
0.07), but this observation was confounded by a tendency towards higher potency of the 
LLDs in the morning group (Mann-Whitney U = 5.906, p = 0.05). The tVAR of the LLD intake 
did not significantly differ between morning and evening LLD intakers (31:29 ± 19:36 min:s 
vs. 46:29 ± 59:03 min:s, p = 0.2).  
4. Discussion 
4.1. Main Findings 
Biomarker response is an intermediate outcome and can reflect the forgiveness of a drug. In 
HIV, asthma or blood pressure drugs, electronic adherence was predictive of biomarker 
outcomes [34, 75, 76]. Safety and effectiveness may be directly linked to the timing 
adherence to drugs with critical pharmacological properties. For the exemplary case of lipid 
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lowering therapy, the impact of intake time variability can be estimated from its effects on 
LDL-cholesterol. LDL-C values typically change within a longer timeframe than in the short 
period of this study. However, significant time variability may occur, even in a short time 
frame. In this study, lower LDL-C values were achieved when a precise timing adherence 
with the LLD was observed, and those patients were more likely to reach their LDL-C 
targets. Remarkably, this finding was independent of the time of day, although advantages 
regarding the efficacy of LLD were attributed to the evening intake, at least for those agents 
with shorter elimination half-lives. Plakogiannis and Cohen found clinical evidence supporting 
the pharmacologically reasonable evening intake of simvastatin, while data for other statins 
remained inconclusive [81]. Statins are not known to be markedly sensitive regarding timing 
adherence. Nevertheless, the results presented here indicate that a regular timing of drug 
intake may be of more importance than the time of day for the optimization of statins’ 
effectiveness. Given the generally lower time variability in the morning intake times, and in 
light of the observed association between LDL-C values and the variation in drug intake tVAR, 
a morning intake of the LLD seems favorable.  
However, the limitations to a general recommendation for morning intake become evident 
when considering the remarkable differences of timing adherence pattern in specific patient 
groups. Retired patients were more likely to take their morning doses regularly over the 
entire week, while working patients showed a higher variability of the first daily dose due to 
a significantly delayed intake on Saturday and Sunday (weekend-effect). A plausible 
explanation for a lower tVAR in the elderly, e.g. a higher valuation of drug therapy due to 
disease experiences, was not supported by BMQ scores, which were not age-dependent. 
Special care should be given to patients with higher concerns, since they showed a higher 
time variability of drug intake. The results presented here confirm previous reports on the 
ability of BMQ scores to predict subjective adherence as measured with the MMAS-8 [36].  
No further contributors to high tVAR could be identified in the sub-study. The use of a 
multidrug punch card may have facilitated the achievement of 100% taking adherence, 
especially for those patients with several intake times per day. Thus, occupational status 
remains the principal factor influencing electronically measured adherence. Further 
personalization of drug intake schedules should thus rely on the individual assessment of 
timing adherence collected by POEMS, unless future studies allow the prediction of timing 
adherence pattern from the patients’ socio-demographic and clinical characteristics. 
When studying adherence to lipid lowering (LL) and antihypertensive (AH) drug therapy in a 
retrospective cohort of 8,506 patients using refill data and the proportion of days covered, 
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Chapman et al. found the number of other prescriptions concomitant to LL and AH therapy 
to be the strongest predictor of non-adherence, followed by age, sex and the time between 
AH and LL therapy initiation [48]. In the presented study, neither the number of drugs nor 
the number of dosing times per day were associated with differences in objective measures 
of adherence, leading to the conclusion that the multidrug punch card reduced the 
complexity of the regimen to an irrelevant factor. Still, age, gender and occupational status 
remained important determinants of adherence. 
4.2. Objectively Measured Adherence and Biomarkers 
Balanced intervals between drug intakes are crucial to prevent fluctuations in plasma levels 
and to avoid the consequences of deprivation and subsequent onset of drug effect. Some 
authors emphasized the need to consider dosing intervals instead of the percentage of 
doses taken, which relies on a pharmacologically naive concept [28]. Time variability of drug 
intake should be interpreted in light of the duration of the action of a drug [25]. In the 
presented study, monitoring of patient’s multiple drug regimen was performed, and this 
enabled the comparison of timing adherence with the requirements of each drug. 
Unfortunately, forgiveness has not been characterized for every drug. Except for oral 
contraception, rationally based procedures to prevent the consequences of drug withdrawal 
are nonexistent. For drugs whose forgiveness exceeds the timing interval, efficacy should 
not be affected, but accumulation and toxicity might be more critical [82]. Considerations on 
time deviations from prescribed schedules have not yet led to regulatory consequences, 
thus only scarce data exist on time variability of drug therapy and clinical consequences in 
outpatients. 
4.3. Strengths and Limitations 
The strength of this study lies in the close monitoring of patient adherence with all oral solid 
drugs. One of the limitations is the use of unblinded electronic adherence monitoring, which 
is inherently associated with biased adherence [83]. Further, the limited duration of the 
monitored period and an artificial and highly adherence-enhancing short term setting may 
explain the extraordinary 100% adherence rate. Finally, the small sample size limits the 
impact and generalization of the results. However, data collected with similar methods are 
scarce and limit the possibility to put the presented findings in the context of previous 
research. 
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5. Conclusion 
Collecting data on multidrug adherence with POEMS allowed the complete delineation of 
the patients’ pattern of timing adherence with all oral solid drugs. Variations in intake 
precision and in dose-to-dose intervals were measured, and with the proven 100% taking 
adherence over the observational period, they could be related to biomarker response. 
Overall, the intake time variability was more precise with morning intakes than with evening 
intakes, and a weekend effect contributed to a remarkable variability in working patients. In 
patients with lipid lowering therapy, a lower time variability of the LLD intake was associated 
with lower LDL-C values, independently of the time of day. Further research is needed to 
confirm the impact of timing adherence on the effectiveness of LLD. Future application of 
POEMS may provide data on adherence patterns and substantiate the rationale for 
personalized intake schedules based on individual adherence reports. 
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2.3.1. SUPPLEMENTARY RESULTS: TECHNICAL PERFORMANCE OF POEMS 
The analysis of data from the above study on the pattern of timing adherence and its 
association to LDL-C target attainment (see section 2.3.) allowed assessing the technical 
performance of the POEMS in a clinical study.  
Methods 
The number of expected removals was calculated from the prescribed dosing regimen. 
Signals of cavities (ghost-events) that did not contain any drug or that were not created 
during the patients study participation (between hand-out and hand-in) were not included in 
the data analysis. Technical problems were identified by visual inspection of the punch card 
and ad hoc verification of the data with the study participants. Missing events were counted 
when the cavities were emptied, but the removal was not electronically recorded. Events 
were classified as invalid when they were caused by false handling of the device or when 
multiple signals were registered for several cavities at the same time. Removals of drugs 
that had to be taken on demand (“bei Bedarf”) were counted separately. 
Results 
The study was completed by 82 patients. All 997 expected removals from regular drug 
intake had actually been executed by the patients according to visual inspection, and 885 
(88.8%) valid removals were registered. The registered removals represented adherence 
data of 78 patients, because POEMS did not report any data in 4 patients (see table 4). 
Technical problems caused 82 missed and 19 invalid events, 16 of which were triggered by 
a nearby removal. Another 11 invalid events were caused by patients who prepared the 
removal of the drugs several hours before actual intake. Electronic adherence records were 
complete in 48 (58.5%) patients with a total of 556 drug removals. 
Table 4. Rate of registered events per patient (regular drug intake). 
Rate of valid 
events per patient 
Patients Expected 
events 
Missing 
events 
Invalid 
events 
Valid 
events 
0% 4 (4.8%) 35 35 0 0 
1-20% 1 (1.2%) 7 6 0 1 
21-40% 2 (2.4%) 35 9 14 12 
41-60% 3 (3.7%) 28 12 0 16 
61-80% 4 (4.8%) 35 5 5 25 
81-100% 68 (82.9%) 857 15 11 831 
Total 82 (100%) 997 82 30 885 
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The registration of another 65 removals of drugs that were taken on demand corresponded 
to the number of cavities that have been emptied when returning the punch card. Time and 
date of the removal was not verified with the patient if the removal pattern was plausible. 
Discussion and Conclusion 
Reliability and robustness of a technical device is critical for the success of a clinical study, 
especially if it is used for measuring a primary or secondary endpoint. The POEMS 
technology allowed registering > 80% of the removals in a large majority (82.9%) of the 
patients. This representative data collection allowed analysing summary statistics of timing 
adherence, and the missing data did not corrupt the study results and interpretation. 
However, quality improvements are necessary to further minimize the rate of missed 
recordings, e.g. by programming electronic checks of battery charge and blister connection 
when initializing the device.  
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Abstract 
Introduction: Reliable and precise measurement of patient adherence to medications is 
feasible by incorporating a microcircuitry into pharmaceutical packages of various designs, 
such that the manoeuvres needed to remove a dose of drug are detected, time-stamped, 
and stored. The principle is called "electronic medication event monitoring" but is currently 
limited to the monitoring of a single drug therapy. Aim: Our aims were introducing a new 
technology; a clear, self-adhesive polymer film, with printed loops of conductive wires that 
can be affixed to multidrug punch cards for the electronic adherence monitoring of multiple 
medication regimens (POEMS), and illustrating potential benefits for patient care. We 
present a preliminary report with one patient experience. Materials and methods: Our 
illustrative case was supplied with a prefilled 7-day multiple medication punch card with unit-
of-use doses for specific times of the day (6 pills in the morning cavity, 2 pills in the evening 
cavity and 1 pill in case of insomnia in the bedtime cavity), with the new electronic film 
affixed on it. Results: The intake times over 1 week were extremely skewed (median intake 
hours at 2:00 pm for the morning doses and at 6:40 pm for the evening doses). After an 
intervention aimed at optimising the timing adherence, the morning and evening intake 
hours became more balanced, with 42.3% of correct dosing intervals (± 3h) for drugs with 
twice daily intake (vs. 0% before the intervention). Discussion: The electronic monitoring of 
the entire therapy revealed an intake pattern that would have remained undiscovered with 
any other device and allowed a personalized intervention to correct an inadequate 
medication intake behavior. POEMS may guide health professionals when they need to 
optimise a pharmacotherapy because of suspected insufficient adherence. Further, knowing 
the intake pattern of the entire pharmacotherapy can elucidate unreached clinical outcome, 
drug-drug interactions, and drug resistance. In the near future, one could imagine that 
medication adherence data over the entire therapy plan would be available as soon as the 
electronic wires are activated, so that a failure to take medication could be detected 
immediately and intervention could be taken if appropriate. 
Keywords: Compliance, adherence, electronic monitoring, multidrug punch card, printed 
electronics, community pharmacy 
1. Introduction 
The ideal measurement of adherence has long since been described [68, 84] and should be 
non-invasive, unobtrusive (to avoid that the drug-taking behaviour of the patient is influenced 
by the device), objective (to generate reproducible data for each subject), reliable (to insure 
that the prescribed dose was really taken at the time of package opening), practical and 
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cheap (to maximize use and minimize costs). It should also yield immediate results and not 
be open to manipulation. Based on these stringent requirements, traditional, indirect 
measures (i.e. which do not demonstrate drug ingestion, such as self-reporting, medication 
diaries, residual pill counting, pharmacy records, clinician opinion) do satisfy many criteria 
[85]. However, they assume rather than prove the patient’s actual drug intake, albeit that 
they cover longer periods of time. On the contrary, direct methods (i.e. detection of the drug 
or a metabolic product in a biologic fluid) prove that a dose of a drug was taken but cover 
brief medication periods. With the emergence of microprocessor technologies in the 1990s, 
the precise timing of medication-taking behaviour with oral solid forms became feasible, and 
revealed a comprehensive picture of an individual’s day-to-day drug intake that neither drug 
serum concentrations nor pill counts would have identified. Although electronic compliance-
monitoring devices (ECMD) are considered to provide the most accurate and valuable data 
[86] and are close to a “gold standard” in measuring adherence, they have been mainly used 
until now as a research tool, owing to their prohibitive cost. Electronic monitoring is used in 
research areas to measure adherence in population or in clinical studies; to assess 
determinants of adherence, and to evaluate the effects of intervention on adherence. On the 
patient level, electronic monitoring allows to calculate dosing intervals, taking and timing 
adherence; to identify specific patterns of medication use including week-end effects, drug 
holidays (discontinuing medication use for 24-72h), toothbrush effect or white-coat 
adherence (increasing adherence several days prior to a medical appointment) and dumping 
(intentionally discarding medication); to identify days of under- and over-consumption; to link 
the timing of doses with the efficacy of the drug and with critical health incident [87] to 
distinguish between probable and improbable drug reactions or side effects [87, 88], and 
finally to give patients insight into their own dosing history. The ECMD use a microprocessor 
embedded in a pill bottle cap or in a storage container [89] that records the precise date and 
time, every instance that the device is opened and closed. The major drawback of the bottle 
is that it monitors only one lead drug and thus requires one cap per medication, while the 
container holds up to one month-supply of different pills in its five inner compartments. Due 
to this setting, data are missing on what was done at each opening; was it to take one or 
more pills, to remove daily pocket doses or to fill a weekly organizer? [90]. Further, both 
devices do not accommodate the use of pillboxes [91].  
The new technology is composed of printed electronics made of a clear, self-adhesive 
polymer film with loops of conductive wires that can be affixed to blister packagings. The 
smart components measure the electrical resistance and record the time of its changes 
when a loop is broken, i.e. when a cavity is emptied. The data are transferred via a wireless 
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communication device to a web-based database. This new technology was first developed 
to fit commercially available standard blister packs [92], avoiding the transfer of pills into an 
ECMD and keeping the primary packaging. We developed further the electronic film 
technology to fit on the rear side of a disposable multidose punch card (Fig. 1).  
 
Figure 1. (A) Front side of a commercially available multidose punchcard (Pharmis GmbH, 
Beinwil am See, Switzerland) with 7 × 4 cavities pre-filled with a patient’s individualized 
medication regimen. (B) Rear side covered with an electronic film of conductive tracks, a 
battery and an antenna, and a microchip housing (Confrérie Clinique S.A., Lausanne, 
Switzerland). 
This “unit-of-use packaging” consists of sealed calendar compartments with several 
medications to be taken together in fixed combination, thus avoiding patients from having to 
use multiple medication packs and bottles. Currently, multidose punch cards are filled 
manually by a host of community pharmacists e.g., in the UK, Switzerland, Germany, France, 
Canada and Australia. With the electronic film applied to a multidose punch card, an 
individualised polytherapy can be monitored by means of the so called Polymedication 
Electronic Monitoring System (POEMS).  
The purpose of this paper is to present an illustrative case using a new technology of 
electronic adherence measurement of multiple medication regimens with oral solid forms, 
and to estimate the possible implications linked to this novel technology. We present a 
preliminary report with one patient experience. 
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2. Materials and Method 
2.1. Extended Case Report 
Our patient is a single, recently retired, 65-year-old, Caucasian male. He lives independently 
(and alone) in an apartment in a medium-sized Swiss city and is in possession of a valid 
driver’s licence. He did have a history of alcohol abuse 20 years previously, which he was 
able to overcome. Epilepsy was diagnosed in 1974 and is currently controlled with 
levetiracetam 1000mg twice daily. He is prescribed paroxetine 20mg once daily for the 
treatment of social phobia and relapsing depression. Persisting, slightly asymptomatic 
anaemia has been repeatedly investigated without conclusive diagnosis. Probationary 
treatment with a vitamin B complex twice daily since October 2010 led to a partial correction 
of the anaemia. Rosuvastatin 20mg and low-dose aspirin 100mg were prescribed once daily 
for secondary prevention after a cardiovascular incident. Hypothyroidism was picked up in 
March 2011 and is being treated with levothyroxine 0.1mg once daily. Zolpidem 10mg once 
daily is being taken when required for difficulty sleeping. The patient was briefly hospitalised 
in May 2010 for breakthrough seizures. His physician was suspecting non adherence with 
antiepileptic drugs, while his pharmacist suspected an overconsumption of sleeping pills 
because the patient would regularly come between the regular refill times, requiring 
additional zolpidem tablets. Since hospital discharge, the patient was using a pill organizer, 
refilled weekly by his community pharmacist. 
The patient was offered by his physician in August 2010 to get his medication intake 
monitored, and he accepted. The pharmacist repackaged the entire regimen in a weekly 7x4-
cavities punch card with POEMS, with six pills in the morning cavity (levothyroxine, 
rosuvastatin, aspirin, paroxetine, vitamin B complex, levetiracetam), two pills in the evening 
cavity (vitamin B complex, levetiracetam) and one pill for sleep disorder in the bedtime cavity 
(zolpidem). The noon cavity was left emptied. The remainder of the patient’s monthly 
medication was stored at the study centre to ensure that no other medication would be 
taken beside that prescribed and individually blistered. The patient was informed of the 
electronic monitoring system and was advised to take his drugs as instructed by his 
physician. 
The following parameters were derived from the electronic reports, where “dose” is defined 
as “unit-of-use drugs” included in one cavity, according to the therapy plan. 
a) percentage overall taking adherence (total doses taken divided by total number of 
prescribed doses) calculated over the duration of the observational period;  
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b) percentage of correct dosing days (days taking prescribed dose divided by total days of 
prescribed dose) calculated over the duration of the observational period; 
c) percentage of correct dosing intervals (number of correct dosing intervals divided by total 
number of prescribed dosing intervals) calculated over the duration of the observational 
period; a dosing interval is defined as correct if the time between doses is within 25% of the 
prescribed dosing interval (± 6h for a 24-hour period and ± 3h for a 12-hour period). 
3. Results 
Laboratory data at baseline showed no abnormalities beside a mild normochromic and 
normocytic anaemia (haemoglobin 132 g/l [norm 140-180 g/l]; red blood cells 4.35 T/l [norm 
4.5-5.5 T/l]). The very low cholesterol level (2.9 mmol/l [norm <5.0 mmol/l]) suggested that 
the patient was taking his lipid lowering agent well. The first weekly report of the monitored 
pill intake is given in Figure 2.  
 
Figure 2. Adherence report over 1 week after inclusion (August 2010). The electronic 
punchcard was handed out on Friday morning, with the first cavity to be opened on the 
Friday evening. The spots (see graph) reflect a pushing through of all drugs contained in one 
distinct cavity as recorded with date and time (see table) by the electronic wires in the film. 
Morning and evening doses are highlighted. Bedtime doses could be taken when needed. 
Key:  ż  c Morning doses ż  } Evening doses ż  · Bedtime doses 
 
ADHERENCE AND BIOMARKERS 
 67  
The patient started his daily activities around noon. Median intake hours, mean intervals 
between doses and adherence parameters are given in Table 1. As intervals between 
morning and evening doses were skewed compared to the theoretical 12-hour dose interval 
for a twice daily intake, the percentage of correct dosing intervals for drugs contained in 
morning and evening doses, such as levetiracetam (intake ± 3h every 12h) was 0%. The 
opening times of the bedtime cavities containing the sleeping pills showed a doubling of the 
dose during the first days of the week, leaving the patient without sleeping pills for the rest 
of the week. 
Table 1. Intake times, intervals between doses and adherence parameters for the two 
periods of adherence monitoring before (August 2010) and after (December 2010) the 
individualised intervention. 
 Before intervention 
(7 days in August 2010) 
After intervention 
(14 days in December 2010) 
Time of intake in the morning 8 
am [median] (interquartile range) 2:00 pm (10h 42min) 5:29 am (6h 08min) 
Time of intake in the evening 8 
pm [median] (interquartile range) 
6:40 pm (2h 49min) 7:09 pm (2h 38min) 
Intervals between morning doses 
[mean ± SD] 21h 51min ± 5h 23h 53 min ± 7h 31min 
Intervals between evening doses 
[mean ± SD] 
24h 50min ± 1h 15min 24h 03min ± 3h 10min 
Intervals between morning and 
evening doses [mean±SD] 6h 57min ± 6h 34min 11h 28min ± 4h 28min 
Intervals between evening and 
morning doses [mean±SD] 
16h 07min ± 7h 28min 12h 25min ± 5h 59min 
Overall taking compliance 100% 102.5% 
Correct dosing days* 100% 100% 
Correct dosing intervals morning 
e.g. Acetylsalicylic acid (24h±6h) 
83.3% 53.8% 
Correct dosing intervals morning 
and evening e.g. Levetiracetam 
(12h±3h) 
0% 42.3% 
*without optional bedtime doses 
A measurement-guided medication management (MGMM) programme [86] was 
implemented by the physician after viewing the records of the polymedication adherence 
monitoring. Providing patients with feedback of their dosing histories has been shown to 
positively modify adherence behaviour, either with cue-dose training [93] or by raising 
awareness of the implications of current behaviour [94]. Thus, an intervention using 
elements of the ACE-ME model (assessment, collaboration, education, monitoring and 
evaluation) [95] was planned with the pharmacist. The method of motivational interviewing 
[96] should be used by the pharmacist, i.e. open-ended questions, reflective listening, 
affirmation, and summarisation to help the patient express his concerns about the 
ADHERENCE AND BIOMARKERS 
 68  
behavioural change, enhance his personal motivation, set goals and arrive at a change of 
plan. The planned intervention should focus on the distorted dosing intervals. The objective 
of the intervention should be the improving of the patient’s timing adherence. After the final 
preparations were made, a session of two hours was scheduled for the intervention and 
took place at the community pharmacy on Thursday, 16th December 2010. The reports of 
the intake pattern were printed out and discussed with the patient. The patient was 
instructed that paroxetine needs to be taken in the morning because of possible activating 
side effects, such as nervousness or difficulty sleeping, which are undesirable in the 
evening. A second aspect was the twice daily intake of the immediate release tablets: 
levetiracetam. The pharmacist explained that intake 12 hours apart would result in constant 
plasma concentrations, whilst minimising concentration-related adverse effects, such as 
hostility/aggression, anxiety, insomnia and nervousness/irritability [97][European Medicine 
Agency (EMA), 2009, last updated 11/2011]. The patient should start on the next day 
morning with the new intake behavior he agreed on. 
The records of the next 14 days subsequent to intervention are shown in Figure 3. A punch 
card was handed out every Thursday afternoon, with the first cavity to be opened on the 
Friday morning. The last visit was scheduled for the morning of Thursday, December 30th. 
Overall taking adherence after intervention was 102.5% due to the anticipated consumption 
of sleeping pills before the last visit (Table 1). Time lapse between the 14 morning doses 
was close to the theoretical 24 hours. The morning-evening and evening-morning intervals 
were close to 12 hours and showed a higher constancy than before the intervention. As a 
consequence, the percentage of correct dosing intervals for drugs contained in morning and 
evening doses, such as levetiracetam (every 12h ± 3h) reached 42.3% compared to 0% 
before intervention. The physician received the records, discussed them with the patient at 
the next visit, prescribed a double dose of the sleeping pills and planed another session with 
the pharmacist aimed at motivating further the patient to persist in keeping his new intake 
pattern.  
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Figure 3. Adherence report over 2 weeks after the intervention (December 2010). The y-axis 
reflects local time after adjusting for winter time (í1h). A punch card was handed out every 
Thursday afternoon, with the first cavity to be opened on the Friday morning. Morning and 
evening doses are highlighted. Bedtime doses could be taken when needed.  
Key:  ż  c Morning doses ż  } Evening doses ż  · Bedtime doses 
4. Discussion 
We present a new and innovative film technology for monitoring adherence to multiple 
medication by means of a single case of a patient implementing a complex dosing regimen. 
To the best of our knowledge, this is the first time that drug intake patterns of an entire 
pharmacotherapy, scheduled at 8am, 8pm and bedtime, have been monitored accurately 
and objectively in real time. The problems suspected over months by the treating physician 
and the community pharmacist in the reported case (seizures due to insufficient adherence, 
overconsumption of sleeping pills) could not be solved satisfactorily with the measures then 
at disposition, like dispensing the medication in a pillbox. Only the electronic monitoring of 
the entire pharmacotherapy revealed the irregular pattern of the medication intake and the 
selective consumption of sleeping pills. The pattern would have remained undiscovered if 
only one lead drug had been tracked e.g., with an electronic pill cap; and even unsuspected 
if the tracked drug had to be taken in the evening (mean interval between evening doses: 
24h 50min). A personalised and targeted intervention could only be set up after the health 
professionals were aware of the distorted medication use. Thus, Polymedication Electronic 
Monitoring System could guide health professionals when they optimise the treatment of 
patients whose unsatisfactory clinical outcome is suspected to depend on insufficient 
adherence behavior. This new technology could thus find its place in ambulatory care e.g., in 
specific patients when physicians suspect any form of deviant adherence, as well as in 
clinical trials e.g., with critical drugs or expensive drugs, when non adherence must be 
excluded with strong certainty. The actual costs of the multidose punch cards are low 
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(around Euro 2.- for one punch card), and the Swiss health insurance reimburse the 
adherence aid delivered by a community pharmacist as a cognitive service. The electronic 
film as research prototypes are at a high price, that will decrease as soon as the production 
can be automated, and reach an affordable price. 
One limitation inherent to the electronic monitoring of medication use is that the patient gets 
no other medication than the individually repackaged drugs, in order to prevent any extra 
medication intake that would not be recorded. The lack of medication stock as well as the 
obligation to have punctual refills might be a constraint too strong for some patients and 
might represent a selection bias in larger studies. However, some patients welcome the 
simplification obtained with one mutidrug punch card and the suppression of the different 
primary packagings. Further, some patients may be reluctant to use this technology because 
they may feel under surveillance. However, when the monitoring is not presented as a 
supervision but as a way to treatment optimisation, one can suppose that the patients will 
accept an electronic monitoring. We observed also a marked curiosity from our patient as 
well as a certain desire to compete with the technique.  
When searching for a gold standard for adherence monitoring, electronic films affixed to 
multiple medication punch cards appear to fill all the criteria, i.e. they are non-invasive, 
unobtrusive, objective, and user friendly. In addition, the transparent compartments on the 
front side facilitate visual verification of the pre-filled medication and contribute to the safety 
of drug intake. The monitoring of a multiple drug regimen depicts the intake times of all 
drugs and thus, enables to evaluate complex drug-effect relationship like drug resistance and 
drug-drug-interactions. Finally, the new system is usable, even when a patient is used to 
storage devices like a pillbox.  
Some studies showed that short message services (SMS) sent automatically to patients at 
the appropriate time without interference of a healthcare professional have positive effects 
on adherence rate [98]. Further, first results with transmission of adherence data through 
telephone connection in real-time showed the feasibility of the immediate monitoring and its 
potential to give feedback when a dose of a drug is not taken. Thus, in the near future, one 
could imagine that medication adherence data over the entire therapy plan would be 
available as soon as the electronic wires are activated, so that a failure to take medication 
could be detected immediately and intervention could be taken if appropriate, like sending a 
SMS reminder. We are well aware that we present a single case to depict new emerging 
fields of monitoring a polymedication. Further studies are needed to confirm the 
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generalizability of our findings and to establish the place of POEMS in ambulatory care and in 
clinical trials.  
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Abstract 
Antiplatelet resistance with aspirin and clopidogrel has been associated with clinical, cellular 
and pharmaco-genetic factors, and non-adherence has been considered as a major 
contributor to resistance in outpatients. We aimed at assessing factors to resistance when 
adherence to the antiplatelet drugs and all other oral solid drugs was controlled for. We 
tested arachidonic acid and/or ADP-induced in vitro platelet aggregation of 82 outpatients 
with chronic aspirin and/or clopidogrel treatment before and after a one week period of 
measuring the patient’s adherence with the polymedication electronic monitoring system 
(POEMS). Resistance was found in 20% (aspirin; n=69) and 25% (clopidogrel; n=32) of the 
patients after monitored adherence. Mean platelet aggregation was not (aspirin) or non-
significantly (clopidogrel) lowered when compared to baseline. Diabetes mellitus and 
inflammation were consistently associated with resistance to both drugs, and CYP2C19 
polymorphisms could not be confirmed as predictors of clopidogrel response. Electronically 
compiled multidrug dosing histories allowed the concomitant intake of high-dose lipophilic 
statins to be identified as a risk factor and revealed that exposure to further drug-drug 
interactions (DDIs) was too low for analysis. Multidrug adherence monitoring allowed thus 
dismissing non-adherence as a major contributor to resistance and analysing the impact of 
DDIs according to the actual exposure to the interfering drugs. Further studies based on this 
methodology are essential to prevent misleading results due to incomplete adherence and 
gain additional insight into the impact of timing adherence on antiplatelet drug response. 
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Bullet points 
What is known on this topic 
x Antiplatelet resistance with aspirin and clopidogrel is caused by clinical, 
cellular and pharmaco-genetic factors and is associated with an increased risk 
of therapeutic failure. 
x Non-adherence was found accountable for antiplatelet resistance in 14% of 
the aspirin users and 22% of the clopidogrel users in studies where 
adherence was estimated from retrospectively measured surrogate markers 
of antiplatelet drug intake. 
x Controversial findings on the impact of drug-drug interactions (DDIs) and 
pharmaco-genetic contributors to antiplatelet resistance are subject of an on-
going debate. 
What this paper adds 
x We present the results of the first study on antiplatelet resistance with 
prospective electronic monitoring of outpatient adherence with all oral solid 
drugs, including those potentially involved in DDIs with the antiplatelet drugs. 
x Non-adherence was dismissed as a major contributor to antiplatelet 
resistance, which persisted in 20% of the aspirin users and 25% of the 
clopidogrel users despite electronic adherence monitoring. 
x Masquerade of non-adherence as antiplatelet resistance and statistically 
diluted effects of DDIs can be limited by electronic monitoring of multidrug 
adherence. 
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Background and Introduction 
Antiplatelet resistance with clopidogrel and aspirin has become a widely debated 
phenomenon in the past decade. A consensus on the definition of has not been reached, but 
antiplatelet drug resistance is commonly understood as the failure of sufficiently inhibiting 
platelet aggregation in patients with prescribed antiplatelet medication. A lack of 
standardisation together with the fact that different commercially available assays do not 
identify the same patients as resistant contributed to the large variation of reported aspirin 
resistance [99-101]. Furthermore, difficulties persist in defining how much platelet inhibition 
is sufficient for protecting patients from clinical events. The multifactorial background of 
antiplatelet resistance is well accepted and involves clinical, cellular and pharmaco-genetic 
factors [102]. Diabetes mellitus and inflammation have repeatedly been associated with 
impaired response to antiplatelet agents. The debate about the impact of pharmaco-genetic 
polymorphisms on clopidogrel response is ongoing [64, 103, 104], and data on the relevance 
of drug-drug interactions (DDI) with proton pump inhibitors (PPI) and other potentially 
interacting drugs on clopidogrel resistance have not always been conclusive [60, 105-108]. 
The DDI between aspirin and ibuprofen is pharmacologically well characterised, but its 
clinical impact is unclear [109]. Many authors have emphasised the role of non-adherence in 
antiplatelet resistance with both aspirin and clopidogrel [99, 110-112]. Data on the impact of 
non-adherence rely on estimates or assumptions from indirect measures such as plasma 
drug or metabolite levels [66, 67]. To our knowledge, no antiplatelet resistance study with 
prospective electronic adherence monitoring has thus far been performed. We used a new 
electronic adherence monitoring system to overcome the observed methodological 
shortcomings [79]. In the reported study, we aimed at determining the incidence of 
antiplatelet resistance with aspirin and clopidogrel in outpatients with monitored adherence 
and at assessing the contributing factors thereof. 
Methods 
This observational cross-sectional trial was approved by the ethics committee of the canton 
Aargau and Solothurn, Switzerland, and has been registered at ClinicalTrials.gov ID 
NCT01039480. The study was conducted in accordance with the Declaration of Helsinki and 
correspondent to the ICH-GCP guidelines. 
Patient Recruiting 
Recruitment was initiated in a convenience sample of 19 general practitioners (GPs) in the 
area of Olten, Switzerland. They approached their patients with on-going prescriptions for 
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aspirin and/or clopidogrel upon a routine consultation at their surgery regardless of the 
diagnosis. For patients who agreed to participate, the GPs transmitted a patient record with 
key demographic and clinical data to the study centre. Within two weeks after reception of 
the record, the patients were contacted from the study centre by phone and invited for a 
first visit in the study centre 1 – 2 weeks later. The patients were requested to bring their 
actual oral solid drugs and, in the meantime, to take their medicines “as usual”.  
Visits, Questionnaires and Adherence Monitoring 
After written informed consent was obtained at the beginning of visit 1 at the study centre, 
reconciliation was made between actual drugs and prescriptions, and the use of over-the-
counter drugs was verified. Any divergences were cleared before all oral solid drugs were 
repacked into a multidrug punch card for one week. The patients underwent venous blood 
sampling and filled in a questionnaire on socio-demographical characteristics and clinical data 
including self-reported height and weight to calculate the body mass index (BMI). 
Additionally, the Beliefs about Medicines Questionnaire (BMQ) [36] and the 8-item Morisky 
Medication Adherence Scale (MMAS-8) [37] were filled in by the patients to measure 
subjective adherence. Patients returned for visit 2 after 7 days, where they brought back the 
empty punch card and again underwent blood sampling. 
The multidrug punch card was equipped with the polymedication electronic monitoring 
system (POEMS) to collect objective data on the patient’s adherence to his entire oral solid 
medication. POEMS consists of a polymer film with imprinted electronic wires connected to 
a microchip that records time and date when a cavity is opened. Further details on the 
POEMS technology and the definition of objective adherence parameters (intake times, 
intervals, time variability of drug intake tVAR) have been outlined elsewhere [79, 113]. 
Patients were classified as diabetics if they had a prescription for oral antidiabetics, insulin or 
both. Laboratory signs of inflammation were defined by a white blood cell count >9 G/l or C-
reactive protein >5 mg/l at visit 1. 
Pharmacological Biomarkers 
Routine clinical chemistry tests were performed on a cobas® 6000 analyser (Roche 
Diagnostics, Rotkreuz, Switzerland) at visit 1. Blood cell counts on Coulter AcTDiff (Beckman 
Coulter, Brea, CA, USA) and in vitro platelet aggregation measurements with the 
MULTIPLATE® assay (Dynabyte, Munich, Germany) were performed at visit 1 and visit 2. 
Pharmaco-genetic analysis in clopidogrel users was done with the CYP2C19+ assay on the 
INFINITI® analyser (AutoGenomics Inc. Vista, CA, USA). The MULTIPLATE® ASPItest 
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(aspirin) and the ADPtest (clopidogrel) were used to specifically test platelet aggregation 
with the respective antiplatelet drug. The TRAPtest was run as a positive control for general 
platelet aggregability. Blood samples were collected with a 21-gauge needle by direct 
venepuncture. Whole blood for the MULTIPLATE® tests was drawn into BD Vacutainer® 
tubes containing 200 U/ml hirudin (Dynabyte, Munich, Germany) after previous collection of 
a serum sample and gently inverted 6-8 times to allow mixture with the anticoagulant. 
EDTA-containing tubes for platelet counts were drawn subsequent to the hirudin tubes in 
order to avoid cross contamination. No further transportation was performed, and the tests 
were carried out between 60 and 120 minutes after sample collection. The manufacturer’s 
proposed reference values for the MULTIPLATE® ASPItest, ADPtest and TRAPtest were 
confirmed in a pre-study with 21 untreated healthy volunteers (10 men, 11 women). 
Accordingly, resistance was defined by aggregation values above the cut off values of 30 
arbitrary units (AU) for the ASPItest and 53 AU for the ADPtest. 
Differences in platelet aggregation values between visit 1 and visit 2 (ǻASPItest for aspirin 
users and ǻADPtest for clopidogrel users) were calculated, with high differences being 
indicative of poor adherence prior to study participation. 
Statistical Analysis 
The sample size estimation was based on a Monte Carlo simulation with adjusted sampling 
for the estimated overall incidence of non-response. A total of 493 evaluable patients were 
required to confirm genetic variability, drug-drug interactions and co-morbidities as 
contributing factors with a power of 80%. Given the exploratory character of this study with 
limited resources, we aimed at including 80 patients to confirm feasibility and plausibility of 
our approach. Normal distribution of the data was tested with the Kolmogorov-Smirnov test. 
Normally distributed values were reported as mean±SD or 95% confidence intervals (CIs). 
Statistical comparisons of continuous variables between patient groups were performed 
with t-test or the Mann-Whitney U test for unpaired samples. Categorical variables were 
expressed in %, and the ȋ2-Test was used to detect an uneven distribution between groups, 
while Fisher’s exact test was used when any expected cell count for a 2 by 2 table was < 
5%. The frequencies of factors to resistance with aspirin were compared between resistant 
and non-resistant patients. Spearmans Rho (ȡ) was used to express correlations between 
continuous variables. The impact of factors to resistance with clopidogrel was analysed by 
comparing the mean platelet aggregation in patients grouped by the respective factor. 
Statistical significance was set at 5%. Statistical analysis was performed with the SPSS 
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software (Statistical Package for the Social Sciences, version 20 for PC, SPSS Inc. Chicago, 
IL, USA).  
Results 
Patient Characteristics 
Between June 2010 and June 2011, 82 patients successfully completed the study and were 
included for analysis (see figure 1). In patients on a dual antiplatelet regimen (n=23), aspirin 
was combined with either prasugrel (n=4) or clopidogrel (n=19). Together with the patients 
with antiplatelet monotherapy, this resulted in two overlapping samples of 69 patients with 
aspirin and 32 patients with clopidogrel. All aspirin users except for one patient with an 
immediate release formulation and two patients with 300 mg aspirin were prescribed enteric 
coated tablets containing 100 mg aspirin. All clopidogrel users were prescribed the standard 
maintenance dose of 75 mg. 
Figure 1. Study flow chart and constitution of the patient samples 
The entire patient sample (n=82) consisted of 58 (71%) men and 24 (29%) women with a 
mean age of 66±10 years and a BMI of 28.1±4.2 kg/m2. Laboratory signs of inflammation 
were found in 15 (18.3%) patients. No platelet counts below 100 G/l were observed and the 
patients’ TRAPtest results (visit 1: 112±30 AU; visit 2: 117±27 AU; reference range: 84-128 
AU) confirmed good general aggregability. An array of clinical chemistry and hematology 
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tests showed results within the expectable range of the studied patient sample. The most 
frequently prescribed concomitant medication consisted of antihypertensives (n=63, 78.8%) 
and lipid-lowering drugs (n=68, 82.9%), while 15 patients (18.3%) received oral antidiabetics 
or insulin. Nineteen patients (23.2%) were smokers. 
Aggregometry and Resistance 
The values of platelet aggregation before and after adherence monitoring are shown in 
figures 2 and 3. Platelet aggregation values exceeding the respective cut-offs for resistance 
at visit 2 were observed for 14 (20.3%) aspirin users and 8 (25%) clopidogrel users, resulting 
in an overall resistance rate of 26%.  
 
Figure 2. Distribution of platelet aggregation in 69 aspirin users at visit 1 (before adherence 
monitoring) and visit 2 (after adherence monitoring). ASPItest values > 30 AU indicate 
resistance. 
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Figure 3. Distribution of platelet aggregation in 32 clopidogrel users at visits 1 (before 
adherence monitoring) and visit 2 (after adherence monitoring). ADPtest values > 53 AU 
indicate resistance. 
The mean platelet aggregation values before and after adherence monitoring did not differ in 
the 69 aspirin users (20.3±19.1 vs. 20.3±19.5 AU, p=1.00, paired t-test) and showed a slight 
tendency towards better aggregation at visit 2 for the 32 clopidogrel users (40.6±22.5 AU vs. 
36.8±23.7 AU, p=0.11, paired t-test). The equality (aspirin) and the low difference 
(clopidogrel) between mean platelet aggregation values at visit 1 and 2 resulted from shifts 
in both directions, which were mostly small and thus attributable to technical and biological 
variability. Relevant absolute ASPItest differences > 10 AU between the two visits were 
observed for 12 aspirin users and resulted in a switch regarding responder status for 4 
patients, 2 in each direction. 
From 10 clopidogrel users with absolute ADPtest differences > 10 AU between the two 
visits, 7 shifted towards a better platelet inhibition (of which 3 patients with ǻADPItest < -30 
AU), while 3 shifted inversely towards a lower inhibition. This led to a switch of the 
responder status in 4 patients, again with 2 in each direction. 
Of the 19 patients on dual antiplatelet treatment with clopidogrel and aspirin, 4 patients 
(21%) with isolated clopidogrel resistance and 1 patient (5%) with combined antiplatelet 
resistance were observed. Isolated resistance with aspirin (when patients responded to 
clopidogrel) was not observed. All three patients with clopidogrel monotherapy and resistant 
to the drug had a history of clinical failure with aspirin. They were switched to clopidogrel, 
but had never been tested for resistance with any of the antiplatelet drugs. 
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Associated Factors of Resistance 
Age and BMI did not differ between resistant patients and responders, neither in aspirin nor 
in clopidogrel users (see table 1). Inflammation and diabetes mellitus were associated with 
resistance to both antiplatelet drugs, but statistical significance was limited to aspirin. 
Additionally, aspirin resistance was significantly more often observed in patients who 
received aspirin only and who were treated for primary prevention. 
Table 1. Distribution of factors to resistance in aspirin and clopidogrel users (n.a.=not 
applicable). P-values refer to the results of t=unpaired t-tests, ȋ2=Pearsons Chi-square test 
or F=Fisher’s exact test. 
 Aspirin Clopidogrel 
Factor 
Study 
sample 
N=69 
Resistant 
patients 
N=14 
p-value 
Study 
sample 
N=32 
Resistant 
patients 
N=8 
p-value 
Age [years] 65±10 65±10 0.965 (t) 65±11 66±8 0.916 (t) 
Women 16 (23%) 4 (29%) 0.642 (F) 7 (22%) 0 (0%) 0.103 (F) 
BMI [kg/m2] 27.8±3.6 30.0±5.8 0.208 (t) 27.6±3.6 27.9±6.9 0.892 (t) 
Diabetes 
mellitus 
13 (19%) 7 (50%) 0.002 (F) 6 (19%) 3 (38%) 0.148 (F) 
Inflammation 14 (20%) 6 (43%) 0.029 (F) 5 (16%) 3 (38%) 0.085 (F) 
Primary 
prevention 36 (52%) 12 (86%) 0.005 (ȋ
 2) n.a.   
monotherapy 
(vs. dual) 46 (66%) 13 (93%) 0.017 (F) 13 (41%) 3 (38%) 0.587 (F) 
 
Non-steroidal anti-inflammatory drugs were taken by 14 (20.3%) aspirin users, of which 5 
patients were prescribed the potentially interfering ibuprofen. Electronic adherence records 
showed that the actual exposure to that DDI was low, as none of the five patients took 
ibuprofen more than once during the observed week. 
Potentially DDI-causing high doses (40 mg) of lipophilic statins were taken by 25 (78%) 
clopidogrel users. Those 16 patients (50%) with concomitant statin intake were over-
represented in the resistant group in comparison to 9 patients (28%) with staggered intake 
(p=0.027). The DDI with PPIs could not be analysed because only 7 patients (22%) were 
exposed and only 4 of them took (es-) omeprazole. 
A total of 18 (56%) clopidogrel users showed polymorphisms of the CYP2C19 gene. 
Heterozygous poor metaboliser (PM) genotypes (CYP2C19*2 or CYP2C19*4) were present 
in 6 (19%) patients, and 10 patients were ultrarapid metabolisers (CYP2C19*17). In two 
patients, compound heterozygous genotypes (CYP2C19*17 and *2 or *9) with unknown 
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phenotype association were found. A tendency towards a higher frequency of the poor 
metaboliser genotypes in resistant patients could not be observed. 
Patients were grouped by the presence of presumed factors to resistance and the mean 
ADPtest differences were calculated to quantify the effect of these factors. With a mean 
ADPtest difference of 0.3 AU (CI: -18.1 – 18.6; p=0.98), platelet aggregation of 
CYP2C19*2/*4 poor metabolisers was almost equal to the wild type patients. Mean ADPtest 
differences of 9.5 AU (CI: -12.5 – 31.5; p=0.38, unpaired t-test) for patients with diabetes 
and 17.3 AU (CI: -5.7 – 40.3; p=0.14) for patients with inflammation were found when 
compared to patients without the respective disease factors. The mean ADPtest difference 
for concomitant vs. staggered intake of  40 mg statin was 16.2 (CI: -5.1 – 37.5; p=0.13). All 
of the p-values in this section result from unpaired t-tests. 
Adherence Measures 
All dispensed punch cards were returned at visit 2 (100% return rate). Visual inspection 
confirmed that all removals were executed (100% taking adherence). Electronic adherence 
data was missing in 4 patients (3 aspirin users and 1 patient with aspirin and clopidogrel) due 
to a deficiency in the recording technology, thus timing adherence was evaluable in 78 
patients (95.1%). The timing of drug intake in the morning (mean intake time 7:33±1:00 h) 
and in the evening (19:01±1:35 h) differed significantly regarding intra-individual variability of 
drug intake (tVAR=34:16min:sec vs. 49:31min:sec; p=0.05, unpaired t-test). The MMAS-8 
(median: 8.0; range 4.5-8.0) and the BMQ sub-scores for necessity (20; 6-25) and concerns 
(8; 5-20) predicted a generally high adherence. No correlation was observed between 
subjective adherence scores and biomarker measures such as ǻASPItest (MMAS-8: ȡ=0.43; 
p=0.73 and BMQ differential: ȡ=-0.002; p=0.99) or ǻADPtest (MMAS-8: ȡ=0.112; p=0.54 
and BMQ differential: ȡ=-0.056; p=0.76). 
Discussion 
Incidence of Antiplatelet Resistance 
The observed incidence rates of 20% resistance with aspirin and 25% resistance with 
clopidogrel after electronically monitored adherence are in the broad range of previously 
reported double-digit incidence rates in ambulatory maintenance settings [66, 67]. However, 
the rates strongly depend on the used definitions, methods and cut-offs. A study with 
healthy volunteers recently revealed a higher consistency of the results if testing for 
antiplatelet resistance was performed after repeated daily administration of low-dose aspirin 
in comparison to testing after exposure to a single dose, especially when using enteric 
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coated tablets [114]. This finding supports our approach to test for antiplatelet resistance in 
patients with chronic low-dose aspirin and monitored adherence. The sensitive ASPItest cut-
off set at 30 AU identified all patients whose platelet aggregation was outside the reference 
range (mean±2 standard deviations) of a sample of treated patients, even if it was lower 
than the aggregation values observed in our pre-study of untreated healthy volunteers 
(reference range 57-113 AU). A less sensitive cut-off of 57 AU would have identified 7.2% 
resistant patients with clearly distinct values from responders. The applied cut-off for 
clopidogrel resistance (53 AU) relied on ADPtest results that were within the reference 
range of untreated blood donors. Trials aimed at the validation of cut-offs have been 
performed and rising evidence supports the clinical prediction from modern platelet function 
tests [19-21]. However, no definite cut-off could be defined under which patients are 
protected from clinical events.  Given the normal bell-shaped distribution of ADPtest results 
in clopidogrel users and in accordance with the understanding of clopidogrel resistance as a 
continuous phenomenon, treating ADPtest as a scaled variable may be preferable [115, 116]. 
The analysis by comparison of mean ADPtest identified the same principal factors 
(inflammation and diabetes mellitus) to be associated with antiplatelet resistance. 
(Non-) Adherence 
Inspection of the returned punch cards and electronic records confirmed complete taking 
and regular timing adherence during study participation. Possibly lower adherence prior to 
study participation did not translate into ASPItest differences, but may explain the non-
significant difference between the ADPtests at visits 1 and 2. Clopidogrel may be less 
forgiving than aspirin, thus rendering the ADPtest more sensitive to detect non-adherence. 
However, adherence monitoring did not influence the number of patients that were below 
the cut-off for resistance. 
Our results do not support the same prominent impact of non-adherence which was notably 
attributed to aspirin resistance in previous reports. In a meta-analysis of 10 antiplatelet 
prevention trials, non-adherence was suggested to range between 12% to 52% [117]. 
Cuisset et al. reported a resistance rate of 14% in outpatient aspirin users that was almost 
completely attributed to non-adherence [66]. Clopidogrel adherence was measured by self-
report in the German Stroke Databank and decreased from 81.6% at three months to 61.6% 
after one year [118]. Serebruany et al.  found a non-adherence rate of 22% in clopidogrel 
users when referring to inactive carboxyl metabolite measurements [67]. The results of 
these studies suggest a substantial proportion of resistance that would disappear after 
controlled exposure. However, the inter-individual heterogeneity in the pharmacokinetics of 
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clopidogrel is well-known and it affects the ability of drug or metabolite measurements for 
adherence assessment [28]. Thus, the conclusions drawn from these results are limited by 
the shortcomings of the applied methods, which could be overcome by our study design 
with prospective multidrug adherence monitoring. 
Other Contributing Factors 
We could confirm a significant impact of inflammation and diabetes mellitus on platelet 
inhibition. Both factors have repeatedly been associated with antiplatelet resistance in 
previous reports [64, 119-121]. Drug-drug interactions with statins, PPI (clopidogrel) and 
ibuprofen (aspirin) have been analysed in the respective samples. The data collected by 
POEMS revealed that the exposure with PPI and ibuprofen was much lower than when 
referring to prescriptions, which rendered analysis unhelpful. Additionally, the precise 
tracking of the exposure to clopidogrel as well as to the potentially interfering drug allowed 
identifying the significant impact of concomitant vs. staggered intake of high dose lipophilic 
statins, which compete with the second step of clopidogrel activation by the CYP3A4 
isoenzyme. The interference by lipophilic statins (atorvastatine and simvastatine) has been 
identified by Lau et al. in retrospective analysis of 47 patients [122]. The results obtained in a 
prospective trial with a flow-cytometry based assay to measure platelet activation supported 
these findings with weak but significant influence of statins on clopidogrel effectiveness 
[108]. Malmström et al. failed to confirm these findings in a prospective trial with 
randomised allocation of 69 patients to simvastatin, atorvastatin or rosuvastatin [123]. Finally, 
a large prospective trial with long-term observation further discharged statins from their 
presumed effect on platelet aggregation [124]. However, none of these trials controlled for 
adherence, neither to the antiplatelet agent nor to the interfering drug. Given the high 
prevalence of non-adherence, these methodological shortcomings may dilute the effect of 
presumed DDIs. The consideration of adherence calls for statistical models to integrate the 
variability of drug exposure as an independent continuous variable [125]. With the POEMS 
employed in our study, the concomitant intake of high-dose lipophilic statins could be 
identified as the most probable factor contributing to clopidogrel resistance. 
Polymorphisms of CYP2C19 in clopidogrel users were not directly associated with improved 
or impaired clopidogrel response. Analysing whether a possible interaction between 
pharmaco-genetic and clinical factors may explain the phenotype is far beyond the power of 
our study. In larger studies, the presence of the CYP2C19*2 variant was significantly 
associated with insufficient antiplatelet response to clopidogrel, while the results regarding 
CYP2C19*17 were less consistent [103, 126-129].  
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Strengths and Limitations 
The strength of our study lies in the precise assessment of the patients’ medication and the 
close monitoring of patient adherence and exposure to drug drug interactions due to the 
monitoring with POEMS. In a pre-study on platelet aggregation with healthy volunteers, the 
manufacturer’s cut-offs were verified, and low general aggregability of the platelets was 
ruled out by TRAPtest. This allowed a reliable classification of the patients according to their 
ASPItest and ADPtest results which remain, like any other biomarker, imperfect surrogates 
of the clinical outcomes  
One weakness is the recruitment performed by the GPs that did not follow a randomised 
procedure. A precise number of the approached patients could not be given. All patients 
whose data were transmitted to the study centre were successfully joined by phone, 
indicating a probably great motivation and a voluntary study participation which may not 
represent the average outpatient population. Thus, a possible recruitment bias cannot be 
excluded. Further inherent limits arise from the small sample size of this explorative study, 
which did not allow quantifying the impact of each of the contributing factors on platelet 
inhibition. Additionally, not all presumed factors to antiplatelet resistance were analysed, like 
e.g. COX-1 polymorphism in aspirin. 
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4. RESPONSE TO VITAMIN B12 SUPPLEMENTATION 
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1. Glossary 
See general abbreviations section. 
2. Project Background 
This study was designed in line with a previous study on “antiplatelet resistance with aspirin 
and clopidogrel” which combined electronic multidrug adherence monitoring with oral solid 
drug treatment and biomarkers. The underlying concept is that biomarker response in oral 
drug therapy can be influenced by incomplete adherence to the prescribed drug regimen. 
Effectiveness in comparison to ideal therapy can be hampered by non-adherence. Electronic 
monitoring of adherence can be used to rule out or to control for non-adherence. This allows 
making a difference between behavioral aspects and pharmacological factors for reduced 
effectiveness in subgroups of patients. The identification of individual factors of non-
response is a prerequisite for personalized interventions to improve response in affected 
patients. The contribution of this project against this background lies in a) the 
characterization of biomarker response of adherence-controlled oral treatment in comparison 
to i.m. treatment and b) the investigation of acceptance of the respective administration 
routes, because low acceptance might constitute a barrier for successful outpatient drug 
treatment. 
3. Project Organisation 
Principal investigator Cyrill Jeger, MD 
Medical practice, Ziegelfeldstr. 5, 4600 Olten 
Co-Investigator Philipp Walter, MSc 
Aarelab AG, Industriestr. 78, 4600 Olten 
Pharmaceutical Care Research Group 
University of Basel 
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   Prof. Dr. Kurt E. Hersberger 
   Pharmaceutical Care Research Group 
   University of Basel 
   Dr. phil. II Isabelle Arnet 
   Pharmaceutical Care Research Group 
   University of Basel 
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4. Rationale 
Biochemically, VB12 deficiency is characterized by subnormal to borderline VB12 values in 
the serum. Holotranscobolamine (holoTC) is the bioactive form of VB12 and has been 
discussed as a more specific and sensitive marker of VB12 deficiency. Functional VB12 
deficiency is characterized by both an increase of methylmalonic acid (MMA) and/or 
homocysteine (hcy). Further laboratory findings are hematological abnormalities such as 
megaloblastic anemia, pancytopenia and hypersegmented neutrophils. Hematological 
changes can be found in the more severe cases, while biochemical findings go in parallel 
with less specific clinical manifestations of VB12 deficiency, but no clear-cut limits exist for 
the prediction of symptoms. 
The true prevalence of VB12 deficiency in the general population is unknown, but 15% of 
adults older than 65 years had laboratory evidence of VB12 deficiency in a population based 
study [130]. In large US surveys, about 6% of the population aged 60 years suffers from 
VB12 deficiency, whereas closer to 20% of the population have marginal VB12 status in later 
life [131]. Etiological factors of VB12 deficiency can be divided into nutritional cause [132, 
133], malabsorption syndromes and other gastrointestinal causes [132]. Pernicious anemia 
typically presents with manifest hematological signs and is associated with antibodies to 
intrinsic factor and/or parietal cells, but will account only for a small proportion of the 
observed cases of VB12 deficiency in the study population [134]. Furthermore, defective 
transport mechanisms due to genetic factors account only for a very small proportion of the 
disease. Drug drug interactions with acid-lowering agents may also play a role in the 
development of VB12 deficiency [135]. VB12 deficiency can result in hematologic, 
neurologic and psychiatric manifestation and is associated with a possibly increased risk of 
myocardial infarction and stroke.  
The treatment of VB12 deficiency consists of vitamin B12 supplementation, which can be 
performed either orally or by i.m. injections. In Switzerland, no high-dose VB12 oral mono-
preparation is currently available, and VB12 supplementation is almost always performed 
with i.m. injections of VB12 [136]. Unlike other European countries, high dose oral VB12 is 
rarely used for the treatment of VB12 deficiency in Switzerland despite that there is 
reasonable evidence of its effectiveness [137-140]. Good response to oral supplementation 
has been observed even in the presence of gastrointestinal diseases that are commonly 
associated with VB12 deficiency. One study showed that VB12 deficiency could even be 
reversed in patients who had undergone gastrectomy [141]. 
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In this study, biomarker response after supplementation with oral and intramuscular VB12 
preparations will be compared in a randomized clinical trial. Electronic adherence monitoring 
will be used to control for non-adherence as a possible confounder in oral treatment. 
Laboratory findings of VB12 deficiency are responsive to treatment. They have specific 
response dynamics, and therefore qualify for the evaluation of VB12 supplementation. 
Oral treatment with VB12 may be superior to i.m. injections in terms of patient acceptance 
and cost-effectiveness [142]. Apart from the comparison of biomarker response, this study 
will help to explore the possible benefits of high dose oral treatment with VB12 in a 
representative population with consideration of adherence issues, patient comfort and cost 
effectiveness of outpatient treatment. 
5. Aims of the Study 
5.1. Primary Aims 
x To compare the biomarker response of oral vs. intramuscular treatment of VB12 
deficiency 
x To explore the dynamics of response reflected by various VB12 associated 
biomarkers 
x To compare subjective acceptance in terms of presumed advantage, preferences 
with oral vs. intramuscular supplementation with VB12 in the view of the patient and 
the physician 
5.2. Secondary Aims 
x To assess the rate of laboratory-confirmed deficiency in patients selected by their 
physician for VB12 deficiency screening 
x To assess clinical, nutritional and demographic factors associated with VB12 
deficiency 
x To assess factors which are associated with poor response to VB12 supplementation 
in general and in the respective groups with oral and i.m. treatment 
x To estimate cost-effectiveness of oral supplementation compared to intramuscular 
injections 
6. Hypothesis 
We hypothesize that… 
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x …patients with oral treatment of VB12 deficiency are not less prone to have 
normalized levels of VB12 associated biomarkers than patients with i.m. treatment 
over the treatment period of 4 weeks. 
x …early biomarker response after week 1 and 2 is predictive of the normalization of 
VB12 levels after 4 weeks of treatment. Low responders at week 1 and 2 are less 
likely to reach therapeutic targets at week 4. 
x …VB12 levels are more sensitive to VB12 supplementation at treatment initiation, 
while response of functional parameters of VB12 deficiency is slower. 
7. Research Plan 
7.1.  Study Design 
Prospective randomized unblinded parallel group trial. A control group with placebo is not 
foreseen due to ethical considerations. 
7.2.  Recruitment 
Patients whose physician has ordered a laboratory test for the biochemical confirmation of 
VB12 deficiency will receive a patient information and informed consent form from the 
laboratory (Information for the patients; Written informed consent form; Accompanying 
letter). In the letter, the patients are asked to bring along the informed consent form to their 
next scheduled visit with their GP, during which the results of the lab test will be discussed. 
Previously, a member of the study team will contact the patients by telephone to provide 
additional oral information if necessary, followed by a telephone-based interview if on 
acceptability (questionnaire Q-A) and on demographics and nutrition (questionnaire Q-DN). 
Patients with serum cobolamin concentrations < 200 pmol/l in whom supplementation with 
VB12 should be initiated according to the physician’s decision will be asked by their GP to 
participate in the biomarker study. Patients who give written informed consent will be 
randomly assigned to the conventional intramuscular treatment, or to the oral treatment 
group. The oral treatment group will be handed out 28 tablets of 1000 ʅg cyanocobolamine 
(B12 “Ankermann”; Wörwag Pharma GmbH & Co, Böblingen, Germany) in a 28 day blister 
supplied with electronic adherence monitoring, while patients in the conventional i.m. 
supplementation group will receive weekly injections of 1000 ʅg cyanocobolamine 
(Vitarubin® Depot 1000 ʅg / 1 ml; Streuli Pharma AG, Uznach, Switzerland, mixed with 
Lidocain 1% 1 ml before injection). The two treatment options will not be blinded, and a 
control group is not foreseen due to ethical reasons. 
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Participation in the acceptance study, which basically consists of two questionnaires on 
acceptance, demographics and nutrition is possible for all patients, regardless of their VB12 
test results and not restricted to patients who give informed consent for the biomarker 
study. 
7.3. Inclusion/Exclusion Criteria 
Inclusion Criteria 
x GP’s prescription for VB12 deficiency testing 
x Age > 18 years 
x Ability to give written informed consent 
x Vitamin B12 serum concentrations < 200 pmol/l 
x and indication for vitamin B12 supplementation according to the GP’s estimation  
Exclusion Criteria 
x Patients with concurrent intake of vitamin preparations containing VB12 
x Patients with a previously diagnosed dementia 
x Patients with known hereditary transcobolamin transportation defects 
x Patients with known hereditary defects that might compromise the tolerance to the 
vitamin B12 “Ankermann” tablets according to the summary of product 
characteristics (Fachinformation Wörwag Pharma GmbH, September 2009) 
x lack of written and/or oral understanding in German, French, Italian or English 
languages 
Patients with laboratory confirmed VB12 deficiencies who qualify for VB12 supplementation 
will be started with the randomly assigned treatment.  
7.4. Study Procedure 
Randomisation 
Randomized allocation to the oral and i.m. treatment groups will take place after successful 
inclusion of the patient in the GP’s office. Randomisation will be performed in random 
permuted blocks of four with the help of a randomisation list that will be generated by a 
statistician that is not involved in the study operation. Subsequently, envelopes containing 
the information on treatment allocation will be delivered to the recruiting physicians in 
multiples of four according the block size. The information will be numbered from 1-60, and 
the physician is asked to open the subsequent envelope for each patient who has been 
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successfully recruited. Stratification groups will not be applied in the randomisation 
procedure, because there is no evidence for inhomogeneous response between different 
patient groups (e.g. sex, age, diagnosis). Rejection of the randomly assigned treatment 
group will not be possible. If a patient is unwilling to accept the assigned treatment, study 
participation is not possible and the treatment will be assigned to the next eligible patient. 
Disposition and Initialization of Treatment 
Standard i.m. treatment will be provided directly in the physician’s office by the treating 
physician. Oral VB12 treatment will be provided to the physician in blisterpacks with 28 
cavities, equipped with the electronic monitoring system, after production at the study 
center by a trained pharmacist. After allocation of a patient to the oral treatment group, a 
patient label will be affixed to the 28-cavity blister and electronic adherence monitoring will 
be initialized. A member of the study team will be in charge to dispense the blister for oral 
treatment and explain to the patient how this device should be used on the same day. 
Treatment Plan 
x Oral VB12 group: daily intake of 1 dose of 1000 ȝg cyanocobolamine from day 0 to 
day 27 
x VB12 i.m.: weekly i.m. administration of 1000 ȝg cyanocobolamine (day 0, 7, 14, 21) 
VB12 Treatment Monitoring 
Patients who gave written informed consent will start with the randomly assigned treatment 
at their next scheduled visit with their physician. On the first day of treatment (day 0), a 
baseline blood sample will be drawn before the first intake of oral VB12 or i.m. application. 
Further blood sampling will be scheduled according to Tab. 1 and response to treatment will 
be measured with a panel of VB12 associated biomarkers (holoTC, Hcy, MMA). 
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Table 1. Visit schedules 
Visit Timing Activity Site of execution 
(S)  Screening Day -14 to -2 Blood sampling General practitioner 
(V0)  Baseline Day 0 
Inclusion General practitioner 
Blood sampling 
General practitioner 
 (before treatment 
initiation) 
Randomization and 
Treatment initiation 
General Practitioner 
(V7)  2nd visit Day 7 (+/-1 day) Blood sampling Clinical laboratory 
(V14)  3rd visit 
Day 14 (+/- 1 
day) Blood sampling Clinical laboratory 
(V28)  4th visit Day 28 (+/- 2 
days) 
Blood sampling Clinical laboratory 
 
 
Figure 1: Study flow chart. PI=patient information, IC= informed consent, Q-
A=questionnaire “acceptance”; Q-DN=questionnaire “demographics and nutrition”. S, V0, 
V7, V14, V28 Æ see Tab. 1. 
7.5.  Outcome Measures 
Primary Outcome Measures 
x VB12 levels and VB12 associated biomarkers holoTC, Hcy, MMA at visits V7, V14, 
V28 
x Patient’s answers to questionnaires on subjective acceptance of oral vs. i.m. 
treatment 
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Secondary outcome measures 
x Electronic adherence parameters VB12 tablets once daily 
x Rates of laboratory-confirmed VB12 deficiency in samples sent for  
VB12 screening (S) 
x Patient’s answers to questionnaires on clinical, nutritional and demographic factors 
x Estimated cost-effectiveness of oral supplementation 
7.6.  Data Collection 
Table 2. Data collection 
Timing  
(referring to Tab. 1) 
Form / 
Procedure 
Filled in… / 
reported by… 
Examples of measures 
Screening (S) 
Laboratory 
prescription GP  
Laboratory Report Clinical laboratory Lab test results 
Before V0  
(baseline visit) 
Informed 
Consent 
Patient; signed by 
patient and 
investigator at V0 
Signed informed consent 
Before 
randomization to 
treatments 
Q-DN: 
“demographics 
and nutrition” Patient 
Patient characteristics 
Nutritional habits,  
clinical characteristics 
Q-A: 
“acceptance” 
Acceptance of oral and i.m. 
treatment 
Baseline visit 
(V0) 
Inclusion and 
Randomization 
GP 
Decision for treatment; if yes 
randomized allocation to 
treatment group 
Laboratory 
prescription Baseline laboratory 
Q-GP: physicians 
questionnaire 
Pre-existing diagnosis 
Study centre 
visits 
(V7, V14, V28) 
Lab report:  
VB12 associated 
biomarkers 
Clinical 
Laboratory 
Baseline and biomarker 
response under therapy 
Final visit 
(V28) 
Adherence 
Report 
Read out data at 
Clinical 
Laboratory 
electronic adherence 
parameters 
 
7.7.  Data Analysis 
Collected data will be verified and checked for plausibility by the co-investigator or a trained 
member of the study team. Relevant data for analysis will then be entered into the study 
database with the following sections: Patient characteristics, clinical data with co-
medication, laboratory data, and adherence data. Descriptive statistics will be performed to 
characterize the study sample. The data will then be analyzed for presence of significant 
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differences in biomarker response between the two treatment groups, and sub-analysis of 
the data will allow assessing factors that are associated with response to treatment. 
Furthermore, associations between adherence data and response with oral treatment will be 
explored. 
8. Expected Results 
We expect to find laboratory evidence of VB12 deficiency in approximately 30% of the 
samples sent for confirmation from general practitioners surgeries. In addition we expect to 
confirm that borderline and deficient VB12 levels go in parallel with eleveated levels of 
homocystein, thus supporting diagnostic strategies that rely on homocystein and/or MMA 
when VB12 results are inconclusive. 
Biomarker response to supplementation is expected to be equally effective in both 
treatment groups. First signs of response with biochemical markers are expected to be 
present after 1-2 weeks of treatment independently of the way of administration. They 
should be predictive for long-term biomarker response after 4 weeks of therapy initiation. 
Non-adherence is expected to be a rare issue in a study with voluntary participation and 
electronic adherence monitoring. Thus, we will not be able to study the impact of non-
adherence on the dynamics of biomarker response. This crucial issue in oral outpatient 
medication should be addressed in a follow-up study evaluating the possible impact of 
adherence aids, if the current study can verify non-inferior biomarker response of adherence-
confirmed oral treatment in comparison to i.m. VB12 supplementation. Given the choice 
between oral and i.m. treatment, most patients are expected to prefer the treatment by the 
oral route. 
9. Sample Size and Statistics 
60 consecutive patients with a newly diagnosed or recurrent, but currently untreated VB12 
deficiency sent from recruiting GP’s to the laboratory for VB12 testing will be integrated in 
the study on biomarker response with oral vs. i.m. treatment. The accompanying study on 
subjective acceptance of the two treatment options will be performed until the aim of 60 
patients with evaluable data in the biomarker response study is reached. 
9.1.  Statistical Considerations 
The primary aim of this parallel group trial is to show that oral VB12 supplementation (daily 
intake of 1000 ʅg cobalamin) is not inferior to intramuscular supplementation (weekly 
injection of 1000 ʅg Cobalamin) in terms of serum cobalamine and homocystein 
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concentrations within the first month of treatment. The response to both treatment options 
is presumed to be homogenous irrespective of age, sex and diagnosis, and stratification is 
not presumed to be necessary.  
Outcomes in terms of serum cobolamin and homocystein concentrations after 4 weeks of 
treatment are presumed to be normally distributed in both groups and treatment groups, and 
groups will have nearly the same size due to block randomization. 
Serum cobolamin and homocystein concentrations can be corrected within the first few 
weeks of supplementation. A randomized trial with oral vs. intramuscular treatment showed 
superior results after 4 months with oral vitamin B12, but successful demonstration of non-
inferiority  is likely to be possible within 1 month (see Fig. 1 and 3 in Reference) [143]. 
Although the therapeutic regimen and the presumed baseline vitamin B12 concentrations are 
slightly different, the trial of Kuzminski et al. has served as a template for the following 
sample size estimation. In contrast to published randomized trials, additional blood sampling 
after week 1 and 2 will be more effective to collect data on short term biomarker response 
[137]. However, sample size estimation for this study is based on assumptions regarding 
outcomes after 4 weeks. Patients are presumed to display baseline cobolamin 
concentrations of 100 – 150 pmol/l. Based on published data, which is in line with the 
experience in our own lab, patients reach levels of approximately 600 pmol/l, with an 
estimated standard deviation of 120 pmol/l (CV=20%). A maximum difference of 100 pmol/l 
will be accepted between mean intramuscular and oral supplementation to accept non-
inferiority of the latter, because this difference to be a clinically meaningless difference. 
Given the above assumptions and if there is truly no difference between the groups with 
intramuscular and oral supplementation, then 50 patients are required to be 90% sure that 
the lower limit of a one-sided 95% confidence interval will be above the non-inferiority limit 
of -100 pmol/l (D = 5%; power (1 – E) = 90%). 
This result has been calculated based on the formula: n = f(D,E) × 2 × V2 / d2 where V is the 
standard deviation and d the tolerated difference to accept non-inferiority. This simplified but 
valid procedure for sample size calculation has a tendency to slightly underestimate the 
required sample size [144]. To minimize the risk of an underpowered trial, the inclusion of 10 
additional patients with evaluable data seems justified. 
9.2. Statistical Analysis 
Statistical analysis will be performed with all complete datasets that could be collected 
during the trial. The hypothesis regarding the biomarker response with oral and 
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intramuscular VB12 supplementation will be tested with a one-sided t-Test for cobolamin 
concentrations and VB12 associated biomarkers such as MCV, percentage of 
hypersegmented neutrophils, holotranscobolamin and homocystein. 
The predictive value of the early biomarker response after 1 and 2 weeks of treatment will 
be tested with a rank correlation test for paired samples with prior correction for the baseline 
variation. 
For the evaluation of the acceptability of the two treatment options, the frequency of 
patient’s answers to questionnaire Q-A will be calculated. The relative frequencies of 
answers in specific patient groups (e.g. males, patients > 60 years) will be compared and 
statistically tested if descriptive analysis suggests a clustering of the data. 
The number of laboratory confirmed deficiency (deficiency: serum cobolamin < 150 pmol/l , 
grey zone: 150 – 220 pmol/l) will be put into relation to the number of patients with 
suspected vitamin B12 deficiency. Patient characteristics (demographic data, diagnosis, 
nutrition) will be compared between patients with and without confirmed vitamin B12 
deficiency. 
If the descriptive analysis reveals evidence for inhomogeneous response to VB12 
supplementation in the study population, an analysis for factors associated with low 
response will be performed. Up to now there is no evidence for an impaired response in 
specific patient groups. 
10. Patient Information 
Patients with a proposal for VB12 testing will be informed about the study by a letter with 
written patient information and informed consent form. All patients will be informed about 
their routine laboratory results irrespective of study participation. Study participants will be 
informed about their performance regarding biomarker response with VB12 supplementation 
at the final visit (V28). The results are submitted to the recruiting GP. If the results at the end 
of study participation show that a patient is unlikely to reach the desired long term response, 
alternative drug regimen or diagnostic procedures in order to reach the therapeutic goals will 
be discussed with the referring physician and proposed to the patient upon the next 
scheduled routine consultation. 
11. Institutional Review 
The study will be carried out according to Swiss law and in consistence with the Declaration 
of Helsinki. The study will be submitted to and approved by an independent ethical 
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committee of the Cantons of Aargau and Solothurn. Registration of the study centre 
(=clinical laboratory) will be applied for by the local authorities (Kantonsapothekeramt 
Solothurn, Dr. pharm. Marco Schärer) and the study will be registered at ClinicalTrials.gov. 
Furthermore, the notification of the study will be proposed to the clinical trials section of 
Swissmedic. 
12 Safety Issues 
12.1.  Safety Considerations 
Patients who participate in the study will not be exposed to drugs other than they would 
receive if they were tested and supplemented with VB12 in a standard care setting. The 
difference to standard care consists in the standardized administration of i.m. injections and 
standardized schedules for response evaluation with biomarker measurements, and in the 
route of administration in patients who receive oral VB12. Patients with oral treatment are 
not expected to experience more adverse events than patients with i.m. VB12 
supplementation. Oral treatment with adherence monitoring is unlikely to be less effective 
than i.m. injections. However, if a patient does not adequately respond to oral treatment, 
this will be disclosed by the laboratory evaluations and can be corrected by therapeutic and 
diagnostic measures mentioned in section #10 after study participation. 
Oral drug disposition in electronically monitored blister packs is not known to constitute a 
risk for participants, since it does not differ from other drug blisters packs and its use will be 
demonstrated carefully. Blister pack preparation will be carried out by pharmacists with the 
help of techniques commonly used in pharmacies to optimize safety in drug dispensing. The 
risks concerning laboratory assessment will be limited to those associated with blood 
sampling, which does not differ from routine blood sampling for in vitro diagnostics. Venous 
blood withdrawal can lead to malaise, vertigo and faint (rare). At the site of venipuncture, 
redness, pains, swelling, blue spots and – infrequently – infection may occur. 
12.2.  Adverse Drug Reaction Reporting 
Serious adverse events (SAEs) will be reported by the principal investigator to the local 
ethics committee within 7 days with the SAE form. Events classified as suspected 
unexpected serious adverse reaction (SUSAR) will be reported by the Sponsor-Investigator 
both to swissmedic and confirmed to the local ethics committee with the CIOMS form 
within 7 days. 
The occurrence, treatment and monitoring of non-serious adverse events that are in line with 
the summary of product characteristics of the IMPs will be documented. A summary of 
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these reports will be integrated in the annual safety report of which copies will be sent to 
the local ethics committee and to swissmedic each year and after study completion. 
13. Patient Confidentiality and Data Protection 
All patient information obtained as a result of the study will be regarded as confidential. 
Clinically relevant results will be transmitted to the referring GP. For data processing, results 
will be made anonymous using a unique study ID number instead of name and surname of 
the patient as soon as identification of the subject is not required any more. The patient 
identification key and the randomisation code will be stored in a separate excel file with 
password protected access. 
Digitised data will be stored in the study centre on a network resource. Access will be 
limited to the study team only.  
The informed consent form will be archived by the investigator in the study centre together 
with the case report forms (GP’s report form, patient’s questionnaires, and laboratory test 
results) in a cupboard accessible only for the investigators. 
14. Disclosure of Data and Publication 
All information obtained in the context of this study will be regarded as confidential, at least 
until the appropriate analysis and review by the principal investigators are completed. For 
publication, first author will be Philipp WALTER, last author will be Kurt E. HERSBERGER 
and in between in undefined order other colleagues who will have made important 
contributions to this project, first of which are – corresponding to the current project team 
composition – Cyrill JEGER and Isabelle ARNET. 
15. Funding 
At the moment of submission, the funding is provided by the research group 
(Pharmaceutical Care Research Group). The involved laboratory (Aarelab, Olten) will provide 
facilities for blood sampling, laboratory infrastructure and will support patient recruitment 
and study operation. Pharmis GmbH (Beinwil a.S., Switzerland) will provide blisters to 
dispense oral VB12. The electronic adherence monitoring technology will be obtained from 
the Confrérie Clinique, CH-Lausanne (ECCT B.V., Eindhoven, NL). The investigators will 
inform the ethics committee if funding will be completed by an industrial sponsor. 
16. Appendices 
No appendices 
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17. References 
See general references section. 
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5. GENERAL DISCUSSION 
In this thesis, we developed a new approach towards the investigation of drug resistance. 
The burden of drug resistance with cardiovascular medication – notably lipid lowering drugs 
and antihypertensives – was estimated in project A from the rate of patients who failed to 
attain their presumed biomarker target values. In this first study, we found that therapeutic 
targets of lipid lowering therapy and antihypertensive therapy were missed by 25.8% and 
36.3% of the patients. Multiple factors may contribute to these impressive rates of patients 
who apparently fail to take full advantage of the prescribed regimen. Non-adherence is 
presumably a prominent contributor which merits consideration in any attempt to enlighten 
the gap between expected and observed biomarker response. Consequently, we developed 
a generic approach to study drug resistance in project B and adapted it to antiplatelet 
resistance with aspirin and clopidogrel. The design of the study involved the recruitment 
setting, study procedures, biomarker assessments and the development of the POEMS 
technology. The combination of electronic adherence monitoring and biomarker 
measurement allowed evaluating inadequate drug response in the light of drug intake 
characteristics of the patients. This approach was set up as a model to uncover contributions 
determined by the patients’ disease state or genetic conditions and contributions that may 
arise from suboptimal execution of the therapy plan. The comprehensive assessment of this 
variety of factors is a prerequisite for tailored interventions in a truly personalised approach. 
The study protocol required the participants to bring all their oral drugs to the study centre. 
Reconciliation between prescribed drugs and actual therapy helped to solve discrepancies 
either with the patient or by contacting the prescribing physician. Often, the physicians’ drug 
record was not up to date with the patients’ current medication. If we were unable to 
resolve discrepancies, the patient was advised to take the drugs the way he was used to. 
According to the study design, adherence monitoring involved both electronic monitoring 
and directly observed therapy (DOT) in the case of an insufficient biomarker response. This 
measure to rule out non-adherence in patients who removed the drug from the blister, but 
discarded it afterwards was not feasible, because patient acceptance was low and the 
potential small increase of data quality did not justify the high burden on study personnel. 
Moreover, such irrational behaviour is unlikely in these patients with voluntary study 
participation, thus DOT was not included in the data analysis. 
The ad hoc preparation of the multidrug blister was the most time-consuming step in on-site 
patient management, but could be well integrated in the workflow. Modifications of the 
therapy plan after reconciliation and dosing instructions after preparation of the patient visit 
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caused a lot of extra-work. Immediate database updates and proper detailed documentation 
was critical to obtain reliable data, because this was hard to correct retrospectively. The 
same is true for the validation of adherence data. Immediate data clearing of raw data at the 
time of acquisition in front of the patient is inevitable for its verification. A data display / entry 
system that facilitates real-time data inspection and documentation would be of great value 
in order to produce high quality data with reduced time effort. 
In project C1, we used the adherence data collected with POEMS for a sub-analysis 
exploring the relationship between subjective and objective adherence parameters and their 
association with biomarkers reflecting the effectiveness of lipid lowering therapy. Most of 
the patients with a prescription for aspirin or clopidogrel, which was an inclusion criterion of 
the parent study, received a lipid lowering drug. Timing adherence with lipid lowering drugs 
is not known to be especially critical for therapeutic effectiveness. However, LDL-C was 
more closely associated with the time variability of the lipid lowering drug intake than with 
morning vs. evening intake. The finding that timing precision is generally better in the 
morning than in the evening may have consequences for drug prescription. Other than in 
retired patients, the weekend effect with a higher than average contribution to time 
variability should be considered in working patients. This delay on weekends merits 
consideration when patients receive drugs for which a precise timing of adherence is 
required. Constant intervals between doses can help to keep fluctuations of drug 
concentrations in body fluids low. Whether fluctuations induced by interval length variability 
are relevant depends on the pharmacologic properties of the compound. However, our 
results with lipid lowering drugs showed an association between the time variability of drug 
intake and LDL-C values even though timing adherence is not known to be especially critical 
for statin therapy. However, such studies have never been performed before and they would 
be of great value for other drugs, especially for presumably non-forgiving drugs. 
We could demonstrate that POEMS is a suitable tool to collect comprehensive data on 
multidrug adherence with oral solid drugs. Descriptive statistics on median intake time and 
time variability of drug intake as well as dosing intervals gave insights on the execution of 
prescriptions in daily practice. It was beyond the scope of this sub-analysis to draw 
conclusions on the clinical consequences of the observed intake behaviour. Future projects 
could employ the technology in a patient cohort with prescriptions for drugs where timing 
adherence is known to be critical for therapeutic efficacy (e.g. antiretroviral drugs for the 
treatment of human immunodeficiency virus. However, the findings from our study confirm 
that i) data acquisition with the help of the POEMS technology in an outpatient setting is 
feasible and ii) significant relationships between objective adherence parameters and 
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intermediate outcomes (biomarkers!) can be found. The results from this exploratory study 
encourages to introduce multidrug adherence monitoring to optimize adherence through 
targeted interventions on one hand and drug development in order to tolerate deviations 
from ideal executions of drug prescriptions on the other hand. 
In project C2, we describe the case of a study participant whose irrational drug intake 
behaviour could be detected and described by multidrug adherence monitoring. A 
pharmacists’ intervention helped to improve objectively measured adherence parameters 
during the follow-up with effects on the biomarker level and potentially on clinical outcome. 
Project D represented the execution of the main study. To our knowledge, this was the first 
study on antiplatelet resistance in outpatients which prospectively controlled for adherence. 
Unlike proposed by previous reports based on different measures of aspirin exposure, our 
results did not confirm that aspirin resistance was mainly attributable to non-adherence [66, 
145, 146]. Resistance with aspirin was significantly associated with diabetes mellitus, but 
mean platelet aggregation was not (aspirin) or only moderately and non-significantly 
(clopidogrel) influenced by adherence monitoring. In the patient sample with clopidogrel, we 
observed a continuous distribution of platelet aggregation, which confirmed the expected 
large intra-individual response variability. Adherence monitoring allowed to precisely 
measuring the exposure to DDIs that were presumably associated with impaired response. 
Without precise tracking of the antiplatelet agent and the co-medication, we would not be 
able to measure the effect of the statin-clopidogrel interaction. 
The multifactorial background of antiplatelet resistance with aspirin and clopidogrel has been 
confirmed by clinical, pharmacological and in vitro data and is beyond debate. However, the 
contribution of non-adherence or imprecise dosing was only measurable with electronic 
adherence monitoring, which has not been done before. Given the irreversible action of 
aspirin and clopidogrel on their respective targets, both drugs are presumed forgiving drugs 
with once daily dosing irrespective of their pharmacokinetic properties. Daily aspirin doses 
lower than 100 mg can sufficiently suppress platelet thromboxane productions in healthy 
subjects [147]. In situations with limited adherence, reducing the dose beyond this standard 
dose may result in an impairment of its antithrombotic efficacy [148]. When platelet turnover 
is increased, higher doses or shortened dosing intervals may be required to compensate for 
the shortened forgiveness of antiplatelet drugs [121]. The pathogenetic role of increased 
platelet turnover in systemic inflammation and diabetes is not definitely clear, but poses a 
plausible background for antiplatelet resistance under these circumstances. 
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This study was designed against the background of a concept of personalised medicine that  
mainly focused on the prediction of safety and efficacy from biochemical and genetic 
markers of the treated patient. Considering the bio-psycho-social background of the human 
nature, we tried to integrate factors associated with the patients’ capacity to comply with 
the prescribed therapy plan in a model to measure the respective impact on outcomes. 
Neither adherence nor pharmaco-genetic factors, but inherent clinical conditions were the 
strongest predictors of resistance in this study. This finding underlines the need to consider 
all – behavioural, clinical and genetic – factors in the assessment of resistance. 
In summary, the execution of projects C and D allowed to collect very helpful results and 
experiences with the new technology to measure and display timing adherence with a 
polymedication regimen in daily life. Essentially, the re-packaging of the patients drugs into 
the multidose punchcard and the electronic registration of drug intake time were well 
accepted by the patients. Contrary to directly observed therapy (DOT) with a high burden on 
patient and study personnel, patients did not feel “over-controlled” or hindered in their daily 
activities by the electronic adherence measurement. Thus, POEMS represented an efficient 
tool to collect reliable and objective adherence data. 
We therefore promote the use of POEMS in project E. In a comparison of biomarker 
response with oral vs. intramuscular injection of vitamin B12, the efficacy of oral 
administration of vitamin B12 may be diluted by impaired adherence in an intention-to-treat 
analysis. Controlling for adherence is essential to bring out the true efficacy of oral vitamin 
B12 substitution. 
The major challenges during this thesis were: 
x To define drug resistance in the context of non adherence 
x To establish the scientific support for this multidisciplinary approach to drug 
resistance 
x To elaborate the study design and methods to analyse the data 
x To design and to adapt the electronic adherence monitoring in collaboration with 
Confrérie Clinique B.V., Veldhoven, The Netherlands 
x To find adequate methods to process data collected by electronic adherence 
monitoring and to link them with characteristics of the therapy plan for a 
comprehensive analysis 
x To successfully promote patient recruiting by general practitioners in an ambulatory 
setting 
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Limitations 
While our approach towards the investigation of drug is generic and can be applied to 
various drugs and settings, the obtained results are specific for an area in Switzerland where 
patients receive many of their prescribed drugs from their self-dispensing physician, not 
from the pharmacy. 
Due to technological deficiencies of this first generation of POEMS devices, we failed to 
register all adherence events. However, there were only 4 patients with completely missing 
adherence data. In other patients, single events were missing, but did not affect the 
calculation of summary statistics of objective adherence parameters. 
This thesis was not supported by 3rd party funding despite multiple attempts to find 
industrial partners. This may in part because the investigated lead drugs either have just run 
out of patent protection (clopidogrel) or have been generic for many decades (aspirin). On 
the other hand, awareness of adherence issues are lacking and non-adherence seems still a 
neglected field in the research and development units of many pharmaceutical companies. 
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6. CONCLUSION 
In conclusion this thesis showed that the investigation of antiplatelet resistance by the 
application of this unique approach with prospective adherence monitoring to all oral solid 
drugs is feasible. We were able to characterise the temporal pattern of drug intake and 
found associations between the timing variability of drug intake and attained LDL-C levels in 
patients with lipid lowering therapy. Considering antiplatelet therapy, we found resistance 
rates of 20% (aspirin) and 25% (clopidogrel), which is in the range of previous reports. The 
actual exposure to DDIs was lower than according to prescriptions. We could analyse the 
timing effect of the DDI between clopidogrel and lipophilic statins and found results that 
supported staggered versus concomitant intake of these potentially interfering drugs. 
Unlike directly observed therapy, POEMS for adherence monitoring during one week was 
well accepted by the study participants. Disease factors were mainly associated with 
antiplatelet resistance, whereas non-adherence was discharged from being a major 
contributor in this outpatient sample. 
The following conclusions could be drawn:  
x The POEMS technology allowed collecting data on multidrug timing adherence which 
has not been reported before. 
x The new technology and procedures were well accepted by the patients. 
x Objectively measured timing adherence parameters are suitable to describe intake 
characteristics of a patient. Significant deviations from prescribed drug intake can be 
observed, and intake characteristics vary in different patients’ groups. 
x The combination of the weekly multidrug blister together with the electronic 
adherence monitoring was effective to rule out non-adherence. 
x The association between the time variability of the LLD intake and LDL-C levels 
suggests an impact of timing adherence on statin effectiveness 
x Antiplatelet resistance in outpatients with maintenance doses of aspirin and 
clopidogrel is common. Approximately 20% of patients with aspirin and 25% of the 
patients with clopidogrel are affected.  
x Aspirin resistance is rather a dichotomous phenomenon, while platelet aggregation 
with clopidogrel is a continuously distributed measure. 
  
CONCLUSION 
 112  
Our recommendations for daily practice are: 
x If there is doubt about the effectiveness of the treatment with aspirin or clopidogrel, 
the investigation by specific in vitro platelet aggregation tests is recommended. If the 
test result does not comply with the expected inhibition of platelet aggregation, the 
further investigation should involve multidrug adherence monitoring to rule out non-
adherence and to measure the exposure to potentially interfering drugs. If the 
insufficient inhibition of platelets persists after one week of multidrug adherence 
monitoring, measures should be taken to optimize antiplatelet therapy. In the case of 
clopidogrel, CYP2C19 genotyping should be part of the workup. Comprehensive 
consideration of the test results, together with medication and clinical data should 
allow finding alternative treatments to prevent the patient from the potential clinical 
consequences of antiplatelet drug resistance. 
x Multidrug adherence measurement may serve as a useful diagnostic tool to disclose 
the timing adherence pattern of patients with polymedication. The adherence report 
is useful to visualize the adherence pattern and may serve as a useful background to 
discuss timing adherence issues together with the patient. 
Recommendations for future research and development: 
x Elaboration of the background for a consensual and stringent definition of “drug 
resistance” 
x Development and integration of data on drug adherence into statistical models in 
order to prevent the dilution or masquerade of effects by the variability of drug 
exposure 
x Study the clinical tolerability of specific drugs towards variability of drug exposure 
x Comparison of drug effectiveness with adherence monitoring as an independent 
variable (e.g. oral vs. intramuscular VB12 substitution) 
x Design of studies specifically aimed at measuring (intermediate) outcomes of drugs 
for which timing adherence is critical 
x Software development for facilitated analysis and interpretation of timing adherence 
data  
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